Blowing the Whistle at the FDA, Jan 2001, exposing Dearborn and how OspA causes immunosuppression rather than, "was a vaccine."
 


01 Oct 2017

Home


File List, RICO

1988 Steere says Lyme is like a B cell leukemia

Assoc Blogs-n-Webs:
TruthCures.org
badlymeattitude.com/
immune2lies.com/
researchfraud.com/
may12.org
meadvocacy.org/
truthbetoldx81
lymecryme
CrymeDiseaseNorway
crymedisease
theothersideofthestretcher
rjspiritualityandtuth
LymeTruthSite

JC-LilnkedIn
KD-Linkedin.com
LD-LinkedIn
JC-academia.edu

KD-academia.edu

 


CDC "SPIDER"

Fungal Exosomes Inhibit Apoptosis

IDSA: "Vaccines serve the mfgs, not their victims"

RICO_filed_USDOJ

BlumenthalAntiTrust Lawsuit

Exosomes, Blebs

Spirochetal_Dementia


PDFs
CDC Admits Fraud, 2016
Dattwyler, 1988
Golightly, 1988
Dressler, 1994
BarbourFish, 1993
Dearborn, 1994
BarbourFishpdf.pdf
 

Pathogenic Fungi

Bush's warcrimes, Oct 2000

Trainer

170708

 

 

923 18 U.S.C. § 371—Conspiracy to Defraud the United States

http://www.justice.gov/usao/eousa/foia_reading_room/usam/title9/crm00923.htm


"In summary, those activities which courts have held defraud the United States under 18 U.S.C. § 371 affect the government in at least one of three ways:

    1. "They cheat the government out of money or property;
    2. "They interfere or obstruct legitimate Government activity; or
    3. "They make wrongful use of a governmental instrumentality.


In this case, the ALDF.com, which consisted of CDC officers as members of this astroturf-, fake non-profit, the ALDF.com and the EUCALB, conspired to falsify the case definition of "Lyme disease" to suit their own commercial enterprise of vaccines and test kits for emerging vector-borne diseases. 

1.    ALDF-CDC Enterprise Conspires to Defraud USA in Dearborn-Vaccine Scam

2.    
Lyme Disease Patents


3.    
Lyme Disease Biomarkers


4.    
Patients Guide to NIHs Post Sepsis Syndrome


5.     The Primers Shell Game (new)

6.   New 16 Scientific Articles on NIH's Post-Sepsis Syndrome as Chronic Lyme /LYMErix disease and "Immunoparalysis"
 

If you're serious about this BULLSHIT, please join us at the OCCUPY JUSTICE this Spring (June, mostly); Serious people only please, no complainers and no talking about your own misery story, Be there for the OTHER GUY (or kid):



“I don’t think it’s appropriate to force people to undergo, to have their children undergo a medical procedure in this country,” Mr. Kennedy said in a segment on KOIN-TV in Salem. “I think it’s against the tenets of our country.”

http://www.washingtontimes.com/news/2015/mar/16/robert-kennedy-jr-presses-states-to-rethink-child-/#ixzz3Uoqhe2Jo

 


 

You can tell there is no real sane leadership in America if we have to tell you what OspA is, while Anthony Fauci says he does not know what OspA is, ... while he has patent for an HIV vaccine with OspA (Pam3) stuck on it 6,911,527 ,... and also a patent for the treatment of OspA disease 5,696,079.  Shit you just can't make up: 

"Illustrative of specific disease states in treatment of which the present invention can be applied are HIV infection and other diseases characterized by a decrease of T-cell immunity, for example, mycobacterial infections like tuberculosis and fungal infections such as cryptococcal disease. This method also can be used in the treatment of secondary infections that occur in patients with suppressed immune systems, such as the opportunistic infections that occur in AIDS patients.


Everyone fusses about no NIH funding when the jerks who are employed by the HHS.gov are all patenteering fools. So now they complain that because they effed up by putting potential personal patent profits before people, they find themselves really behind the global medical research game. 

Who could have guessed that the effing retarded HHS.gov said the very thing that caused MS, RA, Lupus, and most cancers, was a "vaccine?" 

Some of the major Criminal Charge Sheets for the USDOJ OCCUPY and Explainer Handouts are available to download from http://www.ohioactionlyme.org  and the  Bad Ass Cryme Blog

Latest:

https://badlymeattitude.files.wordpress.com/2015/03/patients-guide-to-nihs-post-sepsis-syndrome-2.pdf  

 

Extended Data on the same:  New Science-Policy paper on ME/CFS, - and the CDC's Data on the Failed Autism Vaccines - using the IDSociety.org's and the CDC's own data and Policy-Papers.
 


News from the Bright Side, people; We're sharing our star linguist, Bad Ass Cryme blogger's now hugely popular report on ME/CFS and Post-Sepsis Syndrome - a disease and disorder and name endorsed and reported on by the NIH:
http://badlymeattitude.com/2015/01/05/m-e-cfsfibromyalgialymeautismgws-post-sepsis-syndrome/

 

Criminal Charge Sheets for the USDOJ OCCUPY, May 30th to 4th July, 2015
 

The CDC's Dearborn and Lyme Vaccine Scam (150310)


The testing for Lyme disease was falsified to pass off bogus vaccines and test kits – a chronology:

 

Originally, Lyme borrelia were perceived by the CDC to be just another group of Relapsing Fever organisms.  Borreliae (the whole genus) undergo constant antigenic variation, making vaccines and valid testing impossible except for a flagellin method.  At some point, it was decided by CDC officers that they should commercialize Lyme and other emerging, tick-borne diseases by patenting vaccines and test kits based on recombinant antigens, anyway.  No one knows who gave the CDC the authority to do this, but this decision coincided with the establishment of the fake non-profit, the American Lyme Disease Foundation (ALDF.com), Valhalla, NY, in 1990, by Edward McSweegan, Durland Fish, Gary Wormser, and John J. Connolly, the then-president of New York Medical College in association with Kaiser-Permanente, who are still at NYMC writing MD-training modules.  (CDC is often found in collaboration with Kaiser-Permanente; we knew this even before their “Morgellon’s investigation” scam.)

The ALDF.com is a False Claims-and-Racketeering organization, where the wealthy “sponsors” were apparently given some inside information regarding the companies that would be manufacturing the bogus recombinant vaccines and test kits. Those companies would be given some assurance against the prosecution of the testing scam necessary to pass off these bogus recombinant products. The Defendants, via changing the diagnostic standard, claimed Lyme was not just another Relapsing Fever organism, but some entirely different disease.  Yet, spirochetes were for the last 100+ years known to be permanent brain infections; rodent brains used to be the storage media (Barbour, 1986) before the CDC learned how to freeze-dry spirochetes (1964):
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC373079/pdf/microrev00055-0033.pdf  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC277387/pdf/jbacter00438-0287.pdf 
The ALDF.com Defendants even changed the disease’s name to “Lyme disease” from “Lyme borreliosis.”  The participants in the scam even referred to themselves as an “enterprise” (Arthur Weinstein, 1998).

The Defendants conspired to make Lyme disease largely undetectable. The plan was to vaccinate ~5000 people and send them out in the world to see if they got Lyme disease. They then would test the people who became ill, with a test that only detects 15% of the cases. If Lyme disease is only 15% detectable, the Defendants would be guaranteed to have an at least 85% “effective” vaccine.  If they maliciously discredited the people who became ill as a result of the vaccine itself or vaccine failure (Lyme), then the vaccine would be “safe,” too.  We call both the crime of falsifying the testing and the resultant – and current – bogus testing criteria, “Dearborn.”

The problem with this scam was that the vaccine choice, OspA (Pam3Cys or a tri-acylated lipoprotein), was a fungal antigen, a TLR2/1-agonist, and as such caused immunosuppression in humans. It never could have been a vaccine. Shed fungal antigens like OspA were the very things responsible for the New Great Imitator outcomes. In dogs, Gary Wormser saw the same immunosuppression result with an OspA vaccine:

2000, Modulation of lymphocyte proliferative responses by a canine Lyme disease vaccine of recombinant outer surface protein A (OspA).
"OspA interferes with the response of lymphocytes to proliferative stimuli including a blocking of cell cycle phase progression.”
http://www.ncbi.nlm.nih.gov/pubmed/10865170

 
The short version - and even the technical version -, is that OspA or a triacyl lipopeptide or Pam3Cys gums up the immunity-works.

 

 

“Changed!!??” Yes, They Changed the Diagnostic Standard for Lyme disease.


The following article by Allen Steere is the foundation of the CDC’s original, 1990, “Lyme disease” “case definition” blood test (serology).  It was later falsified at a farce of a serology conference put on by the CDC in 1994 in Dearborn, MI.


1986
, Allen Steere says:
Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness.

“… Using immunoblots, we identified proteins of Borrelia burgdorferi bound by IgM and IgG antibodies during Lyme disease. In 12 patients with early disease alone, both the IgM and IgG responses were restricted primarily to a 41-kD antigen. This limited response disappeared within several months. In contrast, among six patients with prolonged illness, the IgM response to the 41-kD protein sometimes persisted for months to years, and late in the illness during arthritis, a new IgM response sometimes developed to a 34-kD component of the organism. The IgG response in these patients appeared in a characteristic sequential pattern over months to years to as many as 11 spirochetal antigens. The appearance of a new IgM response and the expansion of the IgG response late in the illness, and the lack of such responses in patients with early disease alone, suggest that B. burgdorferi remains alive throughout the illness.”
http://www.ncbi.nlm.nih.gov/pubmed/3531237


1990, CDC published this case definition:
http://www.actionlyme.org/CDC_DOCUMENTS_1990.htm
ftp://ftp.cdc.gov/pub/Publications/mmwr/rr/rr3913.pdf

“Laboratory criteria for diagnosis
”• Isolation of Borrelia burgdorferi from clinical specimen, or

“• Demonstration of diagnostic levels of IgM and IgG antibodies to the spirochete in serum or CSF, or
”• Significant change in IgM and IgG antibody response to B. burgdorferi in paired acute – and convalescent-phase serum samples.” 

That means Lyme disease should be perceived as a relapsing fever organism, undergoing antigenic variation. Victims are only able to produce new, IgM bands if the organism is still alive and not killed by antibiotics.

Steere also wrote in that same 1986 report (above; basis of the 1990 CDC case definition) that all you need is band 41 to diagnose Lyme; just rule out syphilis. That is important to remember: You only need band 41, or the anti-flagellar antibody and the triad of symptoms to diagnose Lyme with common sense rule-outs. The US patent #5,618,533 of Yale’s is for a specific recombinant fragment of Borrelia burgdorferi flagellin. It is an improvement on the band 41-only antibody test, and is an actual FDA-validation according to the FDA’s criteria for the validation of an analytical method (as shown in the Primers Shell Game criminal charge sheet).

Before a diagnosis of Lyme, and of course in all illnesses, it is recommended to rule out blood cancers. The symptoms of Chronic Lymphocytic Leukemia are identical to chronic Lyme or MS, not to mention the fact that Lyme and LYMErix both are known to cause cancer (and MS, Lupus, possibly RA) via the reactivation of latent herpes viruses.  Mycoplasma are also known to be associated with the production of cancer. Chronic, late, neurologic Lyme victims are tolerized to these fungal type-, TLR2/1-agonist bearing diseases. The truth about the “New Great Imitator” is that it is these other, secondary, opportunistic herpes viruses and other bacterial/fungal infections are responsible for that variety show of outcomes.  It’s similar to AIDS.  It is Post-Sepsis Syndrome.

This is the current, 1994, CDC falsified, Dearborn case definition:
http://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm 

“It was recommended that an IgM immunoblot be considered positive if two of the following three bands are present: 24 kDa (OspC)*, 39 kDa (BmpA), and 41 kDa (Fla) (1).
“It was further recommended that an IgG immunoblot be considered positive if five of the following 10 bands are present: 18 kDa, 21 kDa (OspC)*, 28 kDa, 30 kDa, 39 kDa (BmpA), 41 kDa (Fla), 45 kDa, 58 kDa (not GroEL), 66 kDa, and 93 kDa (2).”

This 1994, current, criteria is very different from the 1990 criteria and basically refers to only the late, HLA-linked, arthritis, hypersensitivity response. It came about as a result of research fraud committed by Allen Steere in Europe in 1992.  OspA and B (bands 31 and 34) are notably absent.
 

As an aside, we can assume that the reason the IDSA/ALDF/CDC/Yale Lyme Defendants do not want anyone treated for Lyme is because late in the disease, it’s really about fungal antigen tolerance and cross tolerance, as well as reactivated herpes viruses, or is NIH’s incurable Post-Sepsis Syndrome.  This outcome is paralleled in many other conditions such as the failed Tuberculosis vaccines, Malaria and Epstein-Barr resulting in Burkitt’s lymphoma, etc.  See more at:
http://badlymeattitude.com/2015/01/05/m-e-cfsfibromyalgialymeautismgws-post-sepsis-syndrome/  
http://www.actionlyme.org/SASH_POLICYPAPER_MECFS.htm

Most recently (March 2015) the IDSA had this to say, confirming our supposition:
"Likewise, the use of broad spectrum gram-negative coverage is not recommended in most common, uncomplicated SSTIs and should be reserved for special populations, such as those with immune compromise."
http://www.the-hospitalist.org/article/infectious-diseases-society-of-america-2014-practice-guidelines-to-diagnose-manage-skin-soft-tissue-infections/

Treatment of “Lyme” would allegedly compromise the treatment of severe sepsis infections by creating an environment where those secondary infections acquire antibiotic resistance genes from Lyme victims being treated with the tougher antibiotics.  The truth, however, is that most infectious disease pathogens pick up resistance genes in swine lagoons. Go ahead and look that up in the National Library of Medicine. That should be well known by normal people (excludes the CDC and IDSA).

How Lyme and OspA cause disease we learned from the LYMErix fiasco, because the fungal OspA vaccines caused the same systemic, protean, post-sepsis syndrome, chronic active infections/disease (per Ben Luft and Dave Persing, and the vaccine victims themselves as reported to the FDA through the VAERS; see below for those links and quotes). 

Follow: First, Lyme was a plain old regular Relapsing Fever organism and the “New Great Imitator!" because it caused ALS, Lupus, MS, Cancer, RA, stroke, etc.  Later, at the same time the crooks had a vaccine candidate in early phase trials, it became nothing and a non-disease (psychiatric and hysteria, etc., Barbour and Fish, 1993). We were then about to get “a vaccine for a disease that causes no illness.”  This is still the current position of Yale, CDC, IDSA, and the ALDF/EUCALB: “Lyme patients are not sick, and OspA was a vaccine.”

IDSociety.org likes to say what diseases are-not, but they never say what diseases are. MD-America does not even notice that the CDC and IDSA are insane, even after the FDA ordered LYMErix off the market in February 2002, after Senator Richard Blumenthal (a former USDOJ prosecutor) sued them for Anti-Trust, after Edward McSweegan became America’s infamous NIH employee as America’s one and only “Man With No Work” (Google that), and even after Senators Markey, Blumenthal, et al, ordered the FDA to assure Lyme testing was valid according to the FDA’s criteria.



Continuing the Chronology of Events in Redefining Lyme as a Non-Disease to Pass Off a Bogus Vaccine:

1986
, Edward McSweegan, in a fake whistleblower letter to Senator Barry Goldwater, trashed U.S. Navy to divert their vector borne diseases funding to his buddies at the ALDF.com cabal. See the Navy’s furious response in the link below. McSweegan thinks there can be a vaccine for Relapsing Fever, confirming the paraphysical theory that arrogance is the seed corn or germinal element in true, genuine stupidity and/or the development of a criminal mind:
http://www.actionlyme.org/GOLDWATER_LETTER.htm

 
1988, Raymond Dattwyler, JJ Halperin, et al, & immune-suppressing, seronegative Lyme; supernatant (lipid layer) of borrelia mash causes NK cell anergy or a blunted immune response. Later, Dattwyler tells the FDA Vaccine committee that the seronegative patients are the sickest (now we know why, as shown above where Lyme and LYMErix are the Great Detonators of the latent herpes viruses and expanded or cross tolerance to other antigens than TLR2/1-agonist bearing kinds; in short, they’re double-fatigued and neurologically damaged):


Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi.

"We conclude that the presence of chronic Lyme disease cannot be excluded by the absence of antibodies against B. burgdorferi and that a specific T-cell blastogenic response to B. burgdorferi is evidence of infection in seronegative patients with clinical indications of chronic Lyme disease."

"The disorder in these seronegative patients reflected a dissociation between T-cell and B-cell immune responses, in which the cell-mediated arm of the immune response was intact yet the humoral portion of the immune response to B. burgdorferi appeared to be blunted. This diminished antibody response is in contrast to the T-cell anergy commonly observed in several chronic infections (e.g., infection with Mycobacterium leprae or M. marinum, filiarasis, and some chronic fungal infections (29-33)."
http://www.ncbi.nlm.nih.gov/pubmed/3054554 http://actionlyme.org/DATTWYLER_NK_SUPPRESSION.htm

And:

Modulation of natural killer cell activity by Borrelia burgdorferi.
"Effect of B burgdorferi Culture on Normal PBL
...when lymphocytes are cultured in the presence of growing Bb there is a marked inhibition ( p < .0005 ) of NK activity on days 3, 5, and 7 when compared to lymphocytes cultured in BSKII media in the absence of spirochetes. This effect is not due to a selective depletion or toxicity to endogenous NK since viability studies and monoclonal antibodies demonstrate no significant changes after culture with the organism.
"The inhibition is directly attributable to the organism or its supernatants (data not shown)."
http://www.ncbi.nlm.nih.gov/pubmed/3056196

 
1990, CDC: "Diagnose Lyme as if it was Relapsing Fever" as previously mentioned.
http://www.actionlyme.org/CDC_DOCUMENTS_1990.htm


1990, Allen Steere reports that "chronic, neurologic Lyme won't test positive," uses Dattwyler and Volkman’s Seronegative Lyme T Cell Assay
CHRONIC NEUROLOGIC MANIFESTATIONS OF LYME DISEASE (NEJM)
"METHODS
”Neurological Evaluation…
”If the patient was seronegative according to these methods, the serum was further tested by immunoblotting (25) and peripheral blood mononuclear cells were tested for reactivity with borrelial antigens by proliferative assay. (26)"
http://www.nejm.org/doi/pdf/10.1056/NEJM199011223232102 
http://www.actionlyme.org/STEERES_SERONEG_LYME_ASSAY.htm  http://www.actionlyme.org/DATTWYLER_NK_SUPPRESSION.htm

And what was reference number 26? 
>>> Seronegative Lyme disease; dissociation of the specific T- and B- lymphocyte responses to Borrelia  burgdorferi - by Raymond Dattwyler, et al, see 1988 above. http://www.ncbi.nlm.nih.gov/pubmed/3054554


1990, ALDF.com founded-- a self-proclaimed “entrepreneurial quartet.” includes McSweegan, Fish, Wormser and Connolly. (You will want to look at who are their sponsors and on their board, seriously.)
http://www.actionlyme.org/CONNOLLY_FISH_WEINSTEIN.htm
http://www.actionlyme.org/ALDF_BOARD.htm


1992, CDC officer Allen Steere falsifies testing in Europe:
http://www.actionlyme.org/STEERE_IN_EUROPE.htm
The PubMed links to those 2 reports – no full text available, that is why I got them out of the Yale Medical Library in 2002 and scanned them in are:
Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/8106763
Western blotting in the serodiagnosis of Lyme disease.
http://www.ncbi.nlm.nih.gov/pubmed/8380611

Of those two reports of Steere’s lab shenanigans in Europe, only the second one is made a part of CDC’s Dearborn booklet. The first one – the one left out of the Dearborn booklet  – is where you can see how he falsified the testing for his later monopoly on post-LYMErix-approval for North America, with Corixa, Yale’s L2 Diagnostics and Imugen.

These entities are officially listed on the Securities and Exchange Commission (SEC) as “partners” in sharing licensing of the RICO Monopoly patent with the strain of Borrelia that had dropped an OspA-B plasmid under US Patent 6,045,804. We will come to this later, as it is critical to the whole scam and shows the intent of their entire enterprise. Steere, in Europe used bogus “high-passage” borreliae strains that drop plasmids, and recombinant OspA and B without the lipids attached, helping leave OspA and B out of the diagnostic standard (see the Dearborn criteria above, there is no OspA or B, bands 31 and 34). The lipid parts of the lipoprotein are known to be immune-stimulatory, or to produce antibodies, so they obviously are necessary to come up with a legitimate criteria.


The following is the text (not in the abstract) of what is in the report on exactly how Steere defrauded the U.S. Government and people:
Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis.
“The group 1 strain of B. burgdorferi, G39/40, used in this study and in the previous study of US patients was isolated from an Ixodes dammini tick in Guilford, Connecticut [21]. The group 2 strain, FRG [Federal Republic of Germany], was isolated from Ixodes ricinus near Cologne [22]. The group 3 strain, IP3, was isolated from Ixodes persulcatus near Leningrad [23]. All three strains used in this study were high passage isolates, which were classified by Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT) using 16S ribosomal RNA sequence determination as described [11, 24]. The recombinant preparations of OspA and OspB used in this study were purified maltose-binding protein-Osp fusion proteins derived from group 1 strain B31 [25]. The fusion proteins contained the full-length OspA or OspB sequence without the lipid moiety or the signal sequence…"
http://www.ncbi.nlm.nih.gov/pubmed/8106763 

The following is what it says in the Persing/Schoen/Steere or Imugen RICO Monopoly patent, that shows the intended monopoly - which required that OspA and B be missing from the diagnostic panel and from the spirochetes used to test the human population after the population was vaccinated with OspA:
Method for detecting B. burgdorferi infection
"…Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure."

"The present invention provides a method useful to detect a B. burgdorferi infection in a subject. The method provided by the invention is particularly useful to discriminate B. burgdorferi infection from OspA vaccination, although it is sufficiently sensitive and specific to use in any general Lyme disease screening or diagnostic application. Thus, the method of the invention is particularly appropriate for large scale screening or diagnostic applications where only part of the subject population has been vaccinated or where the vaccination status of the population is unknown. "
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804
 
The monopoly on post-LYMErix-FDA-approval testing for all vector borne diseases in America and Canada was their stated intention (entrepreneurial or enterprise = RICO). Once LYMErix was on the market, a strain of borreliae that did not have the vaccine antigens in it would have to be used. Vaccine efficacy is never assessed with the very same antigen as the vaccine antigen. Otherwise, it would not be known if the victim has the actual infection in question, or that the antibody that shows up came from the vaccine. This Lyme/Vector-Borne Diseases monopoly depended on LYMErix being on the market.  That way, Corixa, L2 Diagnostics and Imugen would be the only labs in the country licensed to use this RICO strain. They would have access to all the human blood to pharm all sorts of DNA data to patent from humans as well as any new and emerging infectious diseases. That was the monopoly: LYMErix and the bogus testing criteria together with Persing’s RICO patent meant even more vaccine patents in the future. The three, Corixa, Imugen and Yale’s L2 Diagnostics, listed themselves as “partners” in a Securities and Exchange Commission announcement and advertised that this test would be available for the vaccinated population. 


The Defendants falsified the “case definition” to leave out neurologic Lyme cases, and they left OspA and B out for a later monopoly on testing and future patents.  And there, you just read that that intention is clearly stated in a patent and method developed by Schoen and Persing in 1995 (US patent 6,045,804), next:

Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection.
http://www.ncbi.nlm.nih.gov/pubmed/8968914 

 


1992, CDC staff, Barbara Johnson and Joe Piesman, own patents with SmithKline that show 2 kinds of Lyme, HLA-linked and non-HLA-linked antigens:

COMPOSITIONS USEFUL IN DIAGNOSIS AND PROPHYLAXIS OF LYME DISEASE 

"Summary of the Invention
"In one aspect, the invention provides isolated B. burgdorferi antigens which are regulated and differentiated by growth of the B. burgdorferi in a tick vector. Novel antigens of the invention are listed below in Table I.
"Certain of these antigens are characterized as being B. burgdorferi B31 strain specific and major histocompatibility complex (MHC) nonrestricted. Certain other of these antigens are characterized as being MHC-restricted."
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19931209&CC=WO&NR=9324145A1&KC=A1

 

Why is the CDC talking about ”MHC-restricted” vs. “MHC non-restricted?”

What we know that to mean is that classic “autoimmune” diseases tend to be MHC-(or HLA-) restricted, or the antigens, due to intermolecular forces, either bind in the HLA groove too strongly, the HLA-antigen complex is released as yet another free, new antigen, or the antigen does NOT bind tightly enough and the antigen falls out of the HLA groove to re-stimulate.

This “autoimmune” only is the new definition Steere claimed in these 1992 reports and at the CDC’s 1994 Dearborn conference.  He falsely claimed Lyme disease is only the HLA- or MHC-arthritis-restricted and threw out the other, meningitis cases.

Yet, here, in their 1992 patents with SmithKline, the CDC mentions the other outcome-- the no- or fewer- antibody result. Therefore, they recognize the two kinds of Lyme: the 15% of the population with the Rheumatoid Arthritis genegtic background or HLA-restricted or arthritis cases,… and the 85% with seronegative, neurologic, long term, New Great Imitator Lyme. 

The 85% of the chronic disease sufferers most likely suffer from the opportunistics (NIH’s “Post-Sepsis Syndrome”) from the imunosuppression that is caused by shed Borrelial TLR2/1-agonist antigens. Regardless, the falsified tests result in more early Lyme cases going undiagnosed and therefore progressing to permanent disability and early death.



1993, Barbour and Fish slam Neurologic Lyme victims in:
The Biological and Social Phenomenon of Lyme Disease
Barbour and Fish admit that Phase I and Phase II trials of OspA vaccines are underway. Therefore, as is shown in the Persing RICO Monopoly patent (US 6,045,804), they already knew the OspA vaccines were causing a disease indistinguishable from vaccine failure, or CHRONIC LYME:
http://actionlyme.org/BarbourFishpdf.pdf



Here would be a good place to show what data was received by the USDOJ in New Haven, CT, on this fraud and RICO scam, because the difference between neurologic Lyme and arthritis Lyme is so clear:



Compare the blots from the two kinds of Lyme in this  (above) July 2003 RICO complaint. On the left with the faint antibody bands is neurological Lyme (the sickest, according to Ray Dattwyler), and on the right are the HLA-linked outcomes of arthritis and acrodermatitis:
http://www.actionlyme.org/USDOJ_COMPLAINT_RICO.htm

Hence, the Defendants left out the neurological outcomes in their Dearborn scam. The whole point of the redefinition of Lyme at Dearborn was to narrow it to just the HLA-linked, arthritis, supposedly autoimmune, hypersensitivity cases. This is how and why they get away with perjury. When the IDSA/Yale Lyme Defendants say “Lyme Disease,” they mean exclusively “HLA-linked arthritis AND NO OTHER SYMPTOMS.” No lawyer was or is aware of this semantics scam.

Jump to 2005; Here Klempner and Wormser re-revealed that “Lyme disease” is just one thing: a bad knee and no other illness signs. However, as shown above, there are two distinct outcomes of Lyme borreliosis. The controversial one (neurologic-, chronic fatigue- Lyme) really does not have a name right now. Therefore, “Lyme disease” is defined as ONLY a bad knee. It’s a legal definition. It’s also criminal one, based on fraud and no consensus, but here is what it is again (2005):

A Case-Control Study to Examine HLA Haplotype Associations in Patients with Posttreatment Chronic Lyme Disease
”… There appear to be at least 2 distinct syndromes after antibiotic treatment. [They have no data on un-treated people, obviously, since they could not ethically conduct such a study-KMD]  One syndrome has localized symptoms that are similar to pretreatment symptoms. Patients with this syndrome often have recurrent episodes of arthritis/synovitis. Results of synovial fluid cultures and polymerase chain reaction (PCR) for B. burgdorferi are generally negative…. [See the DNA/RNA Shell Game report, this is not true  http://www.actionlyme.org/PRIMERSHELLGAME.htm ; it’s a shell game; they use DNA that they know won’t be there in that sequence due to antigenic variation to claim “No Lyme here.”-- KMD] 

“…Patients generally feel well aside from their arthritis symptoms.” http://jid.oxfordjournals.org/content/192/6/1010.full 


Let’s restate what Wormser and Klempner are trying to say in that 2005 report: 
-- The people with the falsified Dearborn case definition of “only an HLA-linked arthritis in a knee” have only an HLA-linked arthritis in a knee and no other symptoms.
-- If you falsify the case definition and say “ONLY the HLA-linked hypersensitivity response of bad knee can be a ‘case’ of ‘Lyme disease,’" you can then, 11 years later say, “Oh, how amazing for us to find only the HLA-linked case definition of arthritis-only is an HLA-linked arthritis-only, and is only a bad knee.“ 

These people are crazy, yes, if that is what you were thinking.

Also, the CDC recently reacted to the Senators' (Blumenthal, Markey, et al) letter to the Office of Policy and Management, where the Senators are forcing the FDA to do their jobs and assure that the testing for Lyme is validated according to their own FDA rules. (See the Primers Shell Game for more on that; http://www.actionlyme.org/PRIMERSHELLGAME.htm.) The CDC is trying to say that the Dearborn method was FDA validated, when it was not:

”Washington – Senator Edward J. Markey (D-Mass.) was joined by Senators Richard Blumenthal (D-Conn.), Elizabeth Warren (D-Mass.), Sherrod Brown (D-Ohio), and Dick Durbin (D-Ill.) in calling on the Obama administration to release draft guidance to ensure appropriate oversight of laboratory developed diagnostic tests (LDTs), which are used to help diagnose specific forms of cancer and other diseases and are not approved by the Food and Drug Administration (FDA). Laboratories initially manufactured LDTs that could be used for low-risk diagnostics or for rare diseases, but with new technology, they have become a staple of clinical decision-making and are being used to diagnose high-risk but relatively common diseases such as ovarian cancer. Recently, the Centers for Disease Control and Prevention (CDC) reviewed a frequently utilized LDT to detect Lyme disease and found “serious concerns” about false-positive results and misdiagnosis. The CDC recommended that the diagnosis of Lyme disease should instead be left to tests approved by the FDA. ...”
http://politicalnews.me/?id=29174&keys=DIAGNOSES-CONDITIONS-MEDICAL-OBAMACARE

Here are the FDA’s rules for the validation of an analytical method:



which were met by Yale’s 1991 Flagellin Method Patent US # 5,618,533 and this report:
Molecular characterization of the humoral response to the 41-kilodalton flagellar antigen of Borrelia burgdorferi, the Lyme disease agent.
The earliest humoral response in patients infected with Borrelia burgdorferi, the agent of Lyme disease, is directed against the spirochete's 41-kDa flagellar antigen. In order to map the epitopes recognized on this antigen, 11 overlapping fragments spanning the flagellin gene were cloned by polymerase chain reaction and inserted into an Escherichia coli expression vector which directed their expression as fusion proteins containing glutathione S-transferase at the N terminus and a flagellin fragment at the C terminus. Affinity-purified fusion proteins were assayed for reactivity on Western blots (immunoblots) with sera from patients with late-stage Lyme disease. The same immunodominant domain was bound by sera from 17 of 18 patients. This domain (comprising amino acids 197 to 241) does not share significant homology with other bacterial flagellins and therefore may be useful in serological testing for Lyme disease.” http://www.ncbi.nlm.nih.gov/pubmed/1894359

As you can see, the FDA has not changed their rules on how to validate a method:
”Under the FD&C Act, the FDA assures both the analytical validity (e.g., analytical specificity and sensitivity, accuracy and precision) and clinical validity through its premarket clearance and approval process.”
http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407409.pdf


Also, Borrelia burgdorferi is closest genetically to B. anserina, an African bird borreliosis, so it is not surprising that Lyme is found all across the United States, being carried by birds:

Many California bird species host the Lyme disease bacterium, study finds:
http://www.latimes.com/science/sciencenow/la-sci-sn-california-birds-lyme-disease-20150225-story.html

See more at: http://www.actionlyme.org/PRIMERSHELLGAME.htm for the phylogeny or the genetics that shows Lyme is closest to B. anserina (from Africa).

Therefore there cannot be any “disease calculator” for Lyme as there fraudulently had been in the past, in an attempt to limit diagnoses. Just as all kinds of Borreliae are everywhere, so is this specific one, burgdorferi.

 

Returning to the Chronology of the Crime


1994, June; FDA LYMErix Meeting (note that June precedes October--when the Dearborn stunt took place-- so the FDA never approved of the Dearborn method, not to mention it was research fraud, and not a consensus):http://www.actionlyme.org/1994_FDA_MEETING_LYMERIX.htm

Transcript of June 1994 FDA Meeting Minutes on Lyme and potential vaccines:

Dr.O’BRIEN:  “I was concerned about your last slide where you said there was a poor correlation between serologic response and clinical disease.  And as I heard you to say, some people who mount better immune responses get worse disease. Did I hear you say that?”

DR. DATTWYLER:  “No, no, I said the reverse. The better responses tended to have better response.  And I should clarify where this is from. This is from antibiotic trials. These are treatment trials of erythema migrans, in which individuals given an antibiotic regimen which was not optimal – we did not know that it was not optimal at the time – the ones that failed to mount a vigorous response tended to do worse, clinically. So, there was an inverse correlation between the degree of serologic response and the outcome.  

“So, individuals with a poor immune response tend to have worse disease."

 

We know why, now, that “individuals with a poor antibody response have worse disease.” Borrelial fungal antigens cause immunosuppression and a classic post-sepsis-like result with chronic active EBV, HHV-6, et al. And we know this is not just from antibiotic treatment as Dattwyler said at this FDA meeting--that the diminished responses are due to the organism or its supernatants, like OspA, and that that is typical for fungal infections:
Seronegative Lyme disease. Dissociation of specific T- and B-lymphocyte responses to Borrelia burgdorferi.
”We conclude that the presence of chronic Lyme disease cannot be excluded by the absence of antibodies against B. burgdorferi and that a specific T-cell blastogenic response to B. burgdorferi is evidence of infection in seronegative patients with clinical indications of chronic Lyme disease.”
”The disorder in these seronegative patients reflected a dissociation between T-cell and B-cell immune responses, in which the cell-mediated arm of the immune response was intact yet the humoral portion of the immune response to B. burgdorferi appeared to be blunted.  This diminished antibody response is in contrast to the T-cell anergy commonly observed in several chronic infections (e.g., infection with Mycobacterium leprae or M. marinum, filiarasis, and some chronic fungal infections (29-33).”
http://www.ncbi.nlm.nih.gov/pubmed/3054554

http://actionlyme.org/DATTWYLER_NK_SUPPRESSION.htm
And:
Modulation of natural killer cell activity by Borrelia burgdorferi.
"Effect of B burgdorferi Culture on Normal PBL
"...when lymphocytes are cultured in the presence of growing Bb there is a marked inhibition ( p < .0005 ) of NK activity on days 3, 5, and 7 when compared to lymphocytes cultured in BSKII media in the absence of spirochetes.  This effect is not due to a selective depletion or toxicity to endogenous NK since viability studies and monoclonal antibodies demonstrate no significant changes after culture with the organism.
"The inhibition is directly attributable to the organism or its supernatants (data not shown)."
http://www.ncbi.nlm.nih.gov/pubmed/3056196


The diminution of antibody response is due to the fungal antigens shed by Borrelia and not antibiotics since this phenomenon is seen in parallel in other human fungal-exposure immunology.  See those other scientific examples, including from the CDC on the failed Autism vaccines and the failed Tuberculosis vaccines, here: http://www.actionlyme.org/SASH_POLICYPAPER_MECFS.htm 



1994, CDC's invitation to participate in the Dearborn event.  Labs were invited; they said the Steere proposal was only, on average, 15% accurate; CDC then blew off these labs’ recommendations:
http://www.actionlyme.org/DEARBORNINVITATION.pdf


1994, October; CDC's Dearborn Booklet .pdf
http://www.actionlyme.org/DEARBORN_PDF.pdf


Dearborn, Who Said What (also summarized for the FDA at their Jan 2001 hearing on adverse events to LYMErix):  http://www.actionlyme.org/DEARBORN_WHO_SAID_WHAT.htm
 
1) Gary Wormser at New York Medical College reports that Steere’s Dearborn proposal method detected 9/59 of IgG cases or is 15% accurate, missing 85% of the cases:
Serodiagnosis in Early Lyme Disease
”Overall, 51 of 59 (86%) convalescent phase serum specimens were reactive by IB [Dearborn criteria Immunoblot-KMD], 35 of which were interpreted as positive; 26 based on IgM criteria, 8 based on both IgM and IgG, and 1 based on IgG criteria…”

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC266355/pdf/jcm00024-0026.pdf

That is, according to Gary Wormser, 9 out of 59 cases were positive to Dearborn later in the disease; Gary Wormser assessing Steere’s Dearborn panel proposal in this report, says it only detects 15% of the cases in IgG.

2) Igenex —Steere’s IgG panel detected 8% of the cases

3) Imugen —Steere’s IgG panel detected 14% of the cases

4) Wisconsin —Steere’s method was 15% accurate

5) UCONN —Larry Zemel was referring to Lyme as comparable to only juvenile rheumatoid arthritis when of course it isn’t. Recommended adding band 50 for children’s blots.

6) Roche— 28% were positive for 5 of 10 Steere IgG bands.

7) Wadsworth— had some different scoring system. Did not report on accuracy of Steere's method

8) Ontario Ministry of Health—did not give an assessment of the Steere proposal (page 86)

9) Lutheran Hospital— 22% were accurate by Steere’s IgG

10) MarDx Labs— recommended adding bands 31 and 34, but were given CDC positive arthritis positive blood to falsely qualify their test strips. Their Western Blot test strips were used in both OspA vaccine trials. MarDx was later sold to an Irish company, Trinity Biotech, Dublin; all the data they had about this crime was taken out of the country.

11) CDC Atlanta— talked about mice, not humans. The mouse criteria was 2 out of three from OspC, 16 kD, 17.9 kD, for the mice.


We got this standard anyway, even though none of the invited participants agreed - not by a long shot.  See the Primers Shell Game reports here or at this link:
http://www.actionlyme.org/PRIMERSHELLGAME.htm  for an explanation of how VALID testing is performed according to the FDA rules, and how Yale knows all about how to validate a method for Lyme (Bb-specific flagellar antigen) and patented it (US 5,618,533). This is all obvious criminal fraud.  Yale owned a valid test for Lyme but did not use it to qualify their other patented product, rOspA, LYMErix.



Who was involved with approving the bogus Dearborn method at Dearborn when all the invited labs said it was only 15% accurate (and FDA criterion for validation)? 

None other than the CDC vaccine patent owners and all the scammers you see here: http://www.actionlyme.org/Dearborn_Who_Approved.htm


 

“Alan Barbour,” “Edward McSweegan,” “Allen Steere,” “Arthur Weinstein,” "The CDC Lyme Disease Group" (Barbara Johnson), etc. (The same people involved in the OspA vaccines scam were involved in falsifying the testing and who were the original members and “advisors” of the ALDF.com.)


A view of the Dearborn event by a participant.  It’s an independent paper about it; Igenex’s Nick Harris’ report published in the Lyme Disease Foundation’s journal:
http://www.actionlyme.org/HARRIS_IGENEX_DEARBORN.pdf

 


Evidence Lyme Defendants knew LYMErix produced the same "multisystem disease" as "Chronic Lyme"


1) Ben Luft said it at the 1998 FDA meeting:

http://www.fda.gov/ohrms/dockets/ac/98/transcpt/3422t1.rtf

BEN LUFT: "The point that I wanted to make in regard to the study is that there is very heavy dependence on serologic confirmation. And when we start thinking about the adverse events, *** it was stated originally when we got the overview of the disease that the disease is really quite protean. And actually the adverse events are very similar to what the disease manifestations are.**** And if you start to, as I think Dr. Hall was eluding to -- if you start to kind of say well how often do you actually become seropositive, you can start to have a different take on when someone has an adverse event or whether it is disease specific or infection specific versus vaccine specific. And I think that that is an important issue that we have to deal with. ..."


2) Dave Persing said it in his RICO patent (above),

Method for detecting B. burgdorferi infection
"…Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure."
 http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804


3) Fish and Barbour trashed Lyme disease victims with their “Social Aspects” report in 1993 (above), paving the way to slander and libel their future LYMErix victims. They reveal that the OspA vaccine trials are underway in that report. This shows intent to cause harm.
The Biological and Social Phenomenon of Lyme Disease
 http://actionlyme.org/BarbourFishpdf.pdf


4) Dave Persing (who worked on this with Robert Schoen, as shown above) and his company Corixa wanted to sell vaccine adjuvants, but they had to drop OspA as a candidate adjuvant because, as Persing said in another patent (applied for May, 2001, while LYMErix was still on the market, harming people; he never said anything to the FDA about it):

Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
"Accordingly, the methods of the invention provide a powerful and selective approach for modulating the innate immune response pathways in animals without giving rise to the toxicities often associated with the native bacterial components that normally stimulate those pathways."
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=/netahtml/PTO/srchnum.htm&r=1&f=G&l=50&s1=6,800,613.PN.&OS=PN/6,800,613&RS=PN/6,800,613


In this complaint to the UN Human Rights Commission and the foreign embassies:
http://www.actionlyme.org/EMBASSIES_CORIXA_TLR_13_JULY_06.htm
it shows that Corixa got an 11 million dollar “biodefense contract” from the NIH and the adjuvants they are allegedly producing are TLR4 agonists, not TLR2/1 agonists like LYMErix, because Persing et al know OspA as an adjuvant is “too toxic in the native form” and  "…Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure," which means they know OspA is too toxic and causes a chronic illness identical to chronic Lyme.


5) In 1998 Yale’s Robert Schoen wrote the following article in the ALDF’s book, Lyme Disease, ACP Key Diseases Series, published in 1998 to coincide with the release of LYMErix onto the market. Once again. Schoen is paving the way, instructing other “doctors” to view LYMErix-injured people and Chronic Lyme victims (which are essentially the same disease, Post-Sepsis Syndrome) through the same victim-blaming lens. 

The article is called Clinical Vignettes, Case 13, A Vaccine Recipient who Develops Arthralgia and Fatigue, page 238-9, and is about what to do with a person who has had the Yale dangerous rOspA non-vaccine.   He says not to test these LYMErix victims and he minimizes their symptoms, knowing that late, neurologic chronic Lyme symptoms are identical to what Schoen says are "nonspecific" (fatigue, meningitis, etc). 

Schoen says the exact reverse in the Persing-Schoen-Corixa-RICO patent (US. Pat. No. 6,045,804 and associated journal report, http://www.ncbi.nlm.nih.gov/pubmed/8968914): "multisystem complaints characteristic of late Lyme." 

WRITES SCHOEN (you can tell this is BS because it does not make any real sense):


”QUESTION

”Is this patient’s presentation compatible with Lyme disease?


”COMMENT

This patient presents with nonspecific symptoms, including arthralgias and fatigue.  Although he lives in an area endemic for Lyme disease, these findings by themselves do not point to Lyme disease.
            “The risks of a false-positive serologic test result in this patient will be significant because the prevalence of Lyme disease in such individuals is low.  More importantly, this patient has already received a Lyme disease vaccine.  Because of this, he will have antibodies against the 31-kd OspA Borrelia burgdorferi protein.  These antibodies will be directed by the Lyme ELISA and will generate a positive test resut.
            “In the absence of specific clinical features suggesting a diagnosis of Lyme disease, the best course of action may be not to do serologic testing for Lyme disease at all. If such testing is to be done in a person who has received the Lyme disease vaccine, it will need to be sent to a laboratory where the Western blot analysis can be done that omits the 31-kd response.”


"CONCLUSION:

"In Lyme disease recipients (sic), Western blot analysis is indicated to distinguish Lyme disease from seroconversion caused by vaccination."

           

Schoen (above) probably means “In Lyme disease vaccine recipients, Western blot analysis is indicated to distinguish disease from seroconversion by vaccination.” 

This does not make a whole lot of sense because Schoen first said not to test them, just blow these people off, essentially, because their symptoms were vague (means, “not a red, swollen knee”).  But then Schoen went on to say that if you MUST test them, use the Persing-Schoen RICO patent method with the OspA-B plasmid missing, making it very clear that the reason OspA and B were left out of the Dearborn standard was to satisfy this subsequent racketeering condition or monopoly on testing, once LYMErix was on the market.  That is why I call this the RICO patent:
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804

This transcript of Schoen’s “Clinical Vignettes” above is in that textbook with the libel and false statements including the Munchausen’s accusations:
http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584/ref=sr_1_fkmr0_2?ie=UTF8&qid=1341914626&sr=8-2-fkmr0&keywords=lyme+disease+rhan+and+evans

See more at http://www.actionlyme.org/SCHOEN_INSTRUCTING_DOCS_TO_BLOW_OFF_LYMERIX_INJUREES.htm


From start to finish, from when the ALDF.com was established in 1990,… to Steere going to Europe in 1992 to falsify the case definition antibody panel and adding the ridiculous ELISA “screening test” (for arthritis only) for a fungal-like disease, … to the CDC falsifying the testing for Lyme at Dearborn in 1994, … to lying to the FDA and the journals about their outcomes of the 2 vaccine trials in 1998, to fake “Guidelines” based on the bogus Klempner non-retreatment non-study in 2001,…. the point of this scam was to create a condition where only they – the CDC staff and the ALDF.com - would be able to capitalize on vector-borne diseases vaccines and test kits. 

They intended to get all the grants, all the royalties, and to define the diseases based on their fake products. 

Most importantly, they wanted this post-:LYMErix monopoly on human blood testing because they could pharm from that not only human DNA and disease susceptibilities, but new vector borne disease DNA to patent.  It was all about the money.  It was all about cornering the market on this new genre of potential diseases resulting from global pollution.

========


Falsifying the Vaccine Trial Results, Part 2 of the Cryme – the Unreadable Western Blots.
 

The 1998 Vaccines Reports (ImuLyme and LYMErix):

LYMErix results (76% "safe and effective"):
http://content.nejm.org/cgi/content/abstract/339/4/209 

ImmuLyme results (92% "safe and effective"):
http://content.nejm.org/cgi/content/abstract/339/4/216
 

From the LYMErix trial, "categories of outcomes:"
http://content.nejm.org/cgi/content-nw/full/339/4/209/T1


YET, here are the Defendants claiming "we can't read our OspA vaccine results" reports, which means they lied in their OspA vaccine safety and efficacy reports, since they both claimed to be using the Dearborn method and MarDx's Western Blot test strips:


1) Yale’s Robert Schoen and Mayo’s/Corixa’s David Persing, with John Anderson,1995-6; the RICO report: http://jcm.asm.org/cgi/reprint/35/1/233?view=long&pmid=8968914


2) Shoen and Persing in their 1995-6 RICO method patent:
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6045804.PN.&OS=PN/6045804&RS=PN/6045804


3) David Persing and Lenny Sigal explaining that the Western Blots of OspA-vaccine victims were not readable (which means whoever was in charge of data safety monitoring like Arthur Weinstein is in big trouble): http://www.journals.uchicago.edu/doi/pdf/10.1086/313920


4) Yale's Robert Schoen in the 1998 Munchausen's Book, instructing MDs to blow off LYMErix-systemically-injured people ("but send the post-vaccination blood to the Yale L2 Diagnostics RICO lab if you must bother to be a physician").

 

They used the bogus Dearborn method, and did not report that their Western Blots were unreadable.  Each vaccine trial report and summary was 2 false claims.

====


In the fall of 1998, the LYMErix vaccine was approved, anyway, by the FDA (the FDA panel being loaded with people like Allen Steere, Robert Schoen, and Vijay Sikand – the very people who ran the OspA trials).  It came onto the market in late 1998 “despite numerous provisos.”

More than 1,000 systemic adverse events were reported through the VAERS from September 1999 to November 2000, whereupon the FDA granted a public hearing, January 31, 2001: http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2.htm

Whereupon, the whistle was blown on Dearborn and how LYMErix actually caused immunosuppression (the FDA did not scan in the last 19 pages of this booklet, which were 19 pages out of the Dearborn booklet, proving no one agreed with Steere's proposal for an antibody panel for a "case definition"):
http://www.fda.gov/ohrms/dockets/ac/01/slides/3680s2_11.pdf

Several months later, in the fall of 2001, Karen Forschner of the Hartford, CT based Lyme Disease Foundation (Lyme.org) delivered to the FDA – in person, a patent owned by Brigitte Huber at Tufts University, where it was declared that OspA was technically a “toxin,” right in the abstract (US Patent 6,689,384). The FDA then gave SmithKline and Yale, the assignee of the LYMErix patent, an ultimatum: “Either you remove LYMErix voluntarily or we will order it off the market.” SmithKline chose to avoid the embarrassment and pulled their own non-vaccine.

We’re still stuck with this bogus Dearborn case definition, despite numerous attempts at lawsuits against IDSA, SmithKline, and filing complaints to the U. S. Department of Justice. It is still very dangerous for the public to be unaware that the average person, or 85% of us – who are the "seronegative patients are the sickest," have no chance of testing positive to this criminal CDC-Dearborn standard, because the actual disease is one of immunosuppression, or is an Acquired Immune Deficiency, or is similar to AIDS with all the opportunistic viral infections and lymphocyte mutations that can’t be treated with antibiotics, alone.

It was said at the time LYMErix was still on the market that this vaccine, via its claimed mechanism of disinfecting ticks with human antibodies (yes, if you can believe it), that LYMErix would turn humans into walking canisters of tick disinfectant, when in fact, LYMErix turned people into walking “cesspools of disease.” The same is true for Chronic Lyme. Chronic Lyme victims’ immune systems are “overwhelmed”- a term used by CDC officer Alan Barbour, when describing what antigenic variation in spirochetes does to humans (US Patent 6,719,983). This is a term you want to remember in case you hear it again: “overwhelmed” immune system means: “turned off.” “Turned off” is the complete opposite of an “inflammatory” or “autoimmune disease.”
 


 

Charge One:  Falsifying the case definition- a CDC Staff Conspiracy; Steere, Barbour, and Johnson

A) CDC officers Allen Steere, Alan Barbour, Barbara Johnson conspired to falsify the case definition for Lyme disease.  [Conspiracy to Defraud, see the ALDF.com as “Astroturf” or a fake non-profit.]
B) Barbour and Johnson own patents from which they stood to profit only if the testing case definition was falsified. [Theft of Honest Services.]
C) Steere falsified the Western Blot case definition panel of antibodies testing in Europe in 1992 via research fraud, leaving OspA and B out of the diagnostic standard using recombinant antigens and high-passage strains that drop plasmids.  This would give the appearance that OspA and B (encoded on the same plasmid so they would have to be dropped together) were not “primary, immunodominant antigens” which was contrary to Steere, et al’s previous claims and the very nature of their alphanumeric nomenclature (“OspA, OspB, OspC, OspD, OspE, OspF, etc” -antigens). 
Steere, allegedly, stood to profit with the secondary outcome of falsified testing – testing with a method that was designed by Steere (in Europe) that would be necessary after an OspA vaccine was on the market.  It left OspA and B out.  OspA and B are encoded on the same plasmid.  Steere’s friends’ companies were to be the only ones licensed to use this method
Steere was involved in a monopoly with RICO entities David Persing (Mayo Clinic and Corixa), Robert Schoen (Yale’s L2 Diagnostics), and Phillip Molloy (Imugen) to capture all the post-LYMErix testing for North America. They publicly claimed in an SEC filing and in public announcements/advertisements that they would be the only labs licensed to test for Lyme “when the vaccination status of the population was unknown” (US patent 6, 045,804), or if it was unknown if a person had had an OspA vaccine or not.    [False Claims, Racketeering]

Charge Two:  Steere added an unnecessary ELISA screening test that only detects late Lyme arthritis in the first step and declared this to be a test for “early Lyme.”
Steere not only added an ELISA as a screening test that of (falsely raising the bar on a total-antibody test) that left out all neurologic outcomes of Lyme as “cases,” but the normal cut-off for a chromatography assay such as this is 3 standard deviations above baseline noise (that means the signal generated by a blank).  Steere used 5 standard deviations for a cut-off - another act of fraud. 
It was never necessary to use a total-antibody test such as an ELISA since Steere himself knew many patients produced low antibody concentrations, having used the Dattwyler-Halperin Seronegative T cell Proliferation Assay to assess “Chronic Neurologic Lyme” victims in 1990.

Charge Three:  CDC officer Barbara Johnson hosted a fake consensus conference in Dearborn, MI, in October, 1994, subsequent to Steere falsifying the testing in Europe with Frank Dressler (a student in Germany).
Johnson sent out invitations to labs across the country that were under the impression the conference would be about standardization of the METHOD of Western Blotting (e.g., what concentration of reagents and strains to use) rather than the interpretation of the Western Blots.  Only MarDx agreed with the antibody panel proposed by A from his European research fraud criteria, but they, MarDx, had been given Lyme-arthritis-positive blood (HLA-linked hypersensitivity response) to qualify their Western Blot test strips.  The average assessment of the ACCURACY (cases that were known to be positive with, for example a DNA method), excluding MarDx, that were shown to be positive with this falsified antibody panel for a “case” of Lyme was 15%.
Johnson ignored all those recommendations, despite inviting them to “participate in the proceedings.”

Charge Four:  Falsifying the OspA vaccines outcomes:
This gang then reported 76% and 92% “safe and effective” OspA vaccines (ImuLyme and LYMErix) when the Western Blots, they later reported, were unreadable.  So, they used a bogus test, the Dearborn Method (they claimed), to assess the outcomes of their vaccines, but they later reported they actually had no idea if OspA vaccines prevented Lyme because they could not read their results.   

Charge Five:  Issuing “Guidelines” to have it appear they believed Dearborn and the vaccines scam were not fraud
Klempner, the Valid Biomarkers of Illness vs. IDSA’s “Guidelines.”
http://www.ohioactionlyme.org/wp-content/uploads/2015/02/Biomarkers1.pdf

The IDSA “guidelines” on the “diagnosis and treatment of Lyme disease” are based on a 1997-2001 “study” by Mark Klempner, and are meant to reinforce the false notion that IDSA thinks Dearborn is valid, as a sort of a “A Good Offense is the Best Defense” maneuver. 
A) Klempner used the Dearborn case definition as a case definition. 
B) He conducted this so called study in the first place after publishing that Lyme was incurable with ceftriaxone even when the spirochetes had no host cells to hide within (1992). 
C) Klempner allegedly “re-treated” patients IV ceftriaxone for 30 days, when 2/3rds of his victims had never had the standard of care 30 days of IV ceftriaxone for this known meningitis in the first place.
D) Klempner is the author of at least one valid biomarker of central nervous system degradation (MMP-130, 1992), yet he used invalid checklists used for psychiatric patients to assess his non-re-treatment outcomes.

Note – Senator Richard Blumenthal admonished IDSA in his lawsuit for a similar instance where JJ Halperin tried to pull an “end-run” around the Blumenthal subpoena, issuing as second set of false guidelines:   http://www.ct.gov/ag/cwp/view.asp?a=2795&q=414284
The IDSA portrayed another medical association's Lyme disease guidelines as corroborating its own when it knew that the two panels shared several authors, including the chairmen of both groups, and were working on guidelines at the same time. In allowing its panelists to serve on both groups at the same time, IDSA violated its own conflicts of interest policy.”


Charge Six: Intent to Cause Harm with slander, libel and perjury.  
This gang trashed the reputations of their Lyme and LYMErix victims inferring they were crazy; the UN complaint is referenced: http://www.actionlyme.org/UN_PETITION.htm

Charge Seven: The Patents show contradictory claims to public claims made by the cabal; each claim should be examined and be compared to each Defendant’s public claims about “Lyme Disease.”
http://www.ohioactionlyme.org/wp-content/uploads/2015/02/Lyme-Disease-Patents8.pdf
The patents make contradictory claims to what is said publicly about Lyme disease. What’s in them are point by point fraud indictments; Lyme is very serious and incurable; OspA and B were left out of the standard to serve a monopoly on testing after an OspA vaccine was on the market; Barbour owns Edwin Master’s Southern Lyme Disease borrelia; LYMErix or OspA was never a vaccine (Persing).

Charge Eight: The DNA/RNA Shell Game – when looking for spirochetes in humans, they use the wrong DNA.  When looking for organisms to patent by patenting their specific flagellin gene, they know how to find Borreliae. http://www.actionlyme.org/PRIMERSHELLGAME.htm

Charge Nine: Congenital Lyme;  Yale staff wrote at least 3 reports on congenital Lyme in autopsy findings and regarding the effect of maternal antibodies on the fetus.  Later, Yale’s Eugene Shapiro said publicly that there never was a known case of congenital Lyme in the Under Our Skin movie:
http://www.actionlyme.org/Congenital_Brain_Infection_of_Newborn_Resulting_in_Death.htm

Charge Ten: Pediatric Assault with a fake vaccine- UConn and Yale.    Testing a known fake vaccine on Czech children, knowing there was none of that kind of OspA in Europe just to see how serious would be the adverse events.  This is technically known as “assault.”
http://www.actionlyme.org/UCONNS_ABUSE_OF_CZECH_CHILDREN.htm

 

 

The “Lyme Disease” Patents  –  the research fraud and racketeering complaint data for the USDOJ to prosecute; This video teaches you how to use the patent databases to search for related conflict of interest or racketeering data.  In the patents you will find all sorts of language contradictory to what the Lyme cabal or IDSA, now, uses publicly. Therefore, these patents MUST all be studied and examined by you.  These are legal patent CLAIMS and therefore, for the most part, truthful.  These individuals can’t very well patent a non-truth or someone else will patent the actual truth, useful for scientific history as well as commercially.

VID10 THE LYME CRYME PATENTS (Feb 15, 2015)
https://www.youtube.com/watch?v=XQB0VFZiKxg

See also:  Cryme Disease video playlist  the rest of the playlist for more crime facts.



This document is a companion (to the video) list of CDC officers and ALDF.com/Yale/NYMC associates who own patents related to Lyme and other TBDs; the Dearborn event was not only research fraud but interest-conflicted, as were the FDA panels to approve LYMErix (they were all the same characters: Steere, Barbour, Schoen, Rahn, Johnson, Weinstein, McSweegan, etc).
=====

 

A little background about this Dearborn/OspA-scam, since it is the central or essence of the crimes:  “Dearborn” refers to the 1994 CDC conference (took place in Dearborn, MI) where the testing for Lyme was falsified, or changed from that which represented the  Lyme spirochete as just another relapsing fever organism,… to something else entirely contrived (not even empirically perceived) and false.  That event is discussed in this video and the other ones in the YouTube series called “Lyme Crymes.”

For years, no one among this CDC/ALDF/Yale.NYMC cabal would admit that rOspA (recombinant outer surface protein A of the Borrelia burgdorferi organism or the Lyme vaccines that came and went) was Pam3Cys, because they couldn’t.  If they said “OspA is Pam3Cys,” everyone would know from officialdom that it was never a vaccine and the ALDF.com’s (now IDSA’s)  whole house of cards would collapse. rOspA is a fungal antigen that causes immunosuppression – the opposite of a “vaccine.”  If OspA was not a vaccine, then the CDC’s 1994 “Dearborn” 2-tiered testing schema was a lie. 

The falsified Dearborn case definition was the lie invented to pass off bogus OspA vaccines.  You can tell for sure because they left OspA and B out (A and B are encoded on the same plasmid so you can’t leave out one without the other) of the diagnostic standard.  One never tests for vaccine efficacy with the same antigen that is the vaccine. 

For example, if I made a recombinant measles vaccine based on a DNA sequence that coded for say, “XYZ” surface antigen, I would not use recombinant “XYZ” surface antigen in the testing schema to see if a person had measles because I would not know if the antibody band was from the organism or the vaccine. 

It was known at least since the late 1980s that people with late neurologic Lyme disease ceased to produce antibodies.  However, the Dearborn case definition (Steere, that is)  rejected those classes of disease – early and late meningitis or chronic neurologic cases - and said instead that only the blatantly, highly immunoreactive class of Lyme victims, those with the HLA-linked or arthritis-linked or hypersensitivity-linked cases, or those who produced abundant IgG antibodies could be called a “case” of “Lyme Disease.”  This falsification of the testing was as much a semantics game was it was straight up research fraud from these DNA patenteers.  This Dearborn event left the sickest people with no disease diagnosis.

If I intended a monopoly on a new diseases set or an entirely new class of diseases,  such as what African vector borne diseases arriving in North America were discovered to be, what would I do?  I’d make sure I got all of it: vaccines, test kits, grants, funding, all future blood testing for all future potentially patentable goodies in that blood, publicity, my name on plaques and statues (like Alan Barbour), awards like an “Astute Clinician Award,”… or, I could be knighted like Simon Wessely, a psychiatrist who helps by calling all the victims of the Lyme scam and Gulf War Illness “crazy” and “terrorists,” and US States naming, like, “Allen Steere Day” after me…

The Dearborn stunt is to the present day, the lie these criminals are trying to defend by issuing fake “guidelines” based on the fraudulent, 2001, Klempner non-retreatment report,
Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.
http://www.ncbi.nlm.nih.gov/pubmed/11450676
and with this cabal’s chronic hystrionics over the development of other tests for Lyme, etc., because that, Dearborn, will be the most serious criminal charge – the homicide charge.  All the ALDF.com and DNA patent-owners, here, have slandered and libeled against Lyme victims, making this not a simply negligent homicide charge.  All of their  derogatory slander and label and trash-talking Lyme and LYMErix victims show “intent to cause harm,” which is not negligent homicide or manslaughter, but murder and maiming.


Barbour, Alan G., CDC officer and participant in the Dearborn conference, owns 30+ patents including the ImmuLyme OspA patent. The ImmuLyme vaccine trial report authors (Sigal, et al) and Barbour assert that one must be sure lipids are attached to all Osps or else they will not be immunogenic, yet Steere’s Dearborn panel was developed from high passage G39/40 and FRG with recombinant OspA and B with no lipids attached, leaving OspA and B out of the case definition panel.

Barbour’s ImmuLyme patent (&Berstrom, Magnarelli) European Patent # (5092/88, DK)

http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5523089.PN.&OS=PN/5523089&RS=PN/5523089


Yale’s LYMErix OspA patent (5,747,294):
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294

ImmuLyme trial result (falsified; used Dearborn, blots were unreadable):

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

http://www.ncbi.nlm.nih.gov/pubmed/9673299

LYMErix trial result (falsified; used Dearborn, blots were unreadable):

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.
http://www.ncbi.nlm.nih.gov/pubmed/9673298

Barbour says OspA will not work as a vaccine due to antigenic variation, 1992:
Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and characterization.
http://www.ncbi.nlm.nih.gov/pubmed/1339462

Fikrig and Flavell say OspA will not work as a vaccine due to “selection pressure” or antigenic variation, 1995:
Selection of variant Borrelia burgdorferi isolates from mice immunized with outer surface protein A or B.
http://www.ncbi.nlm.nih.gov/pubmed/7729870

 

1992-1994.  Steere Falsifies Test in Europe: uses “high passage strains” and “OspA and B without the lipid attached” to leave OspA and B out of the standard for his later monopoly on vector borne diseases testing.  Only Corixa, Imugen and Yale were to be licensed to use the RICO strain patent by Dave Persing (US Patent # 6,045,804)
Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/8106763

“The group 1 strain of B. burgdorferi, G39/40, used in this study and in the previous study of US patients was isolated from an Ixodes damini tick in Guilford, Connecticut [21].  The group 2 strain, FRG [Federal Republic of Germany], was isolated from Ixodes ricinus near  Cologne [22].  The group 3 strain, IP3, was isolated from Ixodes persulcatus near Leningrad [23].  All three strains used in this study were high passage isolates, which were classified by Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT) using 16S ribosomal RNA sequence determination as described [11, 24].  The recombinant preparations of OspA and OspB used in this study were purified maltose- binding protein-Osp fusion proteins derived from group 1 strain B31 [25].  The fusion proteins contained the full-length OspA or OspB sequence without the lipid moiety or the signal sequence -"
Full Text @ http://www.actionlyme.org/STEERE_IN_EUROPE.htm
Dearborn:  http://www.actionlyme.org/DEARBORN_PDF.pdf
See in the Dearborn booklet: none of the labs agreed with this Dearborn proposal in that Dearborn pdf.  (Except MarDx Labs, which was given arthritis-positive blood to qualify their Western Blot strips prior to Dearborn; MarDx was then was given both vaccine trial contracts; MarDx was then sold to an company in Ireland, taking all the fraud data with them; Trinity Biotech was the name of the company that bought MarDx).
The CDC sent labs an invitation to participate, but then CDC blew them all off:
http://www.actionlyme.org/DEARBORNINVITATION.pdf

 

Barbour also patented Masters’ disease or STARI while the crooks played the DNA/RNA shell game
http://www.actionlyme.org/PRIMERSHELLGAME.htm
to pull the wool over Edwin Masters’ eyes and to say “There is no ‘Lyme’ in Missouri or the south.”  To patent a unique species, you have to patent the flagellin gene.  The same should be true for diagnostics – using unique recombinant flagellins from all Borreliae.

Telford Phylogeny with Masters’ Amblyomma Borrelia:
Lone star tick-infecting borreliae are most closely related to the agent of bovine borreliosis.
http://www.ncbi.nlm.nih.gov/pubmed/11158095

Barbour’s Patent for Masters’ disease or something close to it [either lonestari or barbouri; the phylogenetic data says they are the same in 16S RNA and only slightly different in the flagellin gene (96% homology), so both evolved from theileri, which is cow relapsing fever; one species is now called barbouri and the other is called lonestari, but really they are Masters disease, since he was the one who for years claimed there was a Lyme-like illness in the south, associated with a Lyme-like rash and tick bite]:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,932,220.PN.&OS=PN/5,932,220&RS=PN/5,932,220


Johnson, Barbara J., CDC officer, Ft. Collins, CO., owner of 5 patents in Europe with SmithKline, talks about differences in HLAs of mice, referring to their tendency to produce HLA-linked hypersensitivity responses or not, meaning she is aware that the same applies to humans.
CDC’s BJ Johnson oversaw this Dearborn-Falsification-of-Lyme-Testing stunt (Oct 1994).  She said to not use high passage strains, yet high passage G39/40 and FRG (Federal Republic of Germany) were what Steere used to develop the Dearborn panel along with recombinant OspA and B with no lipids attached.  This was done, again, to assure OspA and B were not included in the Dearborn panel, … to facilitate what Steere, Corixa, L2 Diagnostics and Imugen intended to do after LYMErix was on the market, … which was to monopolize the Lyme or tick-borne diseases testing market where “the vaccination status was unknown.” RICO patent 6.045,804]

Johnson’s Patents (5 in all):
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19931209&CC=WO&NR=9324145A1&KC=A1

Dearborn Booklet http://www.actionlyme.org/DEARBORN_PDF.pdf

 

Fikrig and Flavell – own both the only scientifically valid method to detect Lyme and also own the LYMErix OspA patent.  ***Their FDA-valid flagellin method was not used to assess the outcome of LYMErix because they knew not only did LYMErix not work because Lyme is a Relapsing Fever organism and undergoes antigenic variation (OspA itself, Fikrig and Flavell said, undergoes antigenic variation or “selection pressure” and would be no good as a vaccine), but Pam3Cys or TLR2/1 agonists (OspA is Pam3Cys) are fungal and cause immunosuppression in most people – especially people without Steere’s alleged HLA-linked hypersensitivity responses.***

OspA patent

http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294

Fikrig and Flavell’s (Yale’s) Valid (per FDA) flagellin method patent 5,618,533:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,618,533.PN.&OS=PN/5,618,533&RS=PN/5,618,533

The PubMed report that goes with the Yale FDA-validated flagellin method (detects 94.4% of all cases, including earliest and late neurologic), 1991:
Molecular characterization of the humoral response to the 41-kilodalton flagellar antigen of Borrelia burgdorferi, the Lyme disease agent.
http://www.ncbi.nlm.nih.gov/pubmed/1894359

Fikrig and Flavell say OspA will not work due to antigenic variation:
Selection of variant Borrelia burgdorferi isolates from mice immunized with outer surface protein A or B.
http://www.ncbi.nlm.nih.gov/pubmed/7729870


Padula and OspC – says Borrelia burgdorferi strain B31 has little to no OspC in it, meaning whoever Western Blots with this strain will be leaving OspA, B and C out of the standard.  If you have those bands, you will be told you do not have Lyme, yet they are the “primary, immunodominant antigens,” which was why they got the assignments A, B, C, etc.  SmithKline used this strain, B31, to WB LYMErix victims and claimed to be using the Dearborn method to detect Lyme or vaccine failure.

Padula OspC patent: USPatent No.
5,620,862
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,620,862.PN.&OS=PN/5,620,862&RS=PN/5,620,862

Padula OspC – not in strain B31 PubMed report:
Molecular characterization and expression of p23 (OspC) from a North American strain of Borrelia burgdorferi.
http://www.ncbi.nlm.nih.gov/pubmed/8225587

 

Persing, Schoen and the RICO-within-the-RICO patent – this patent shows the intention of Steere’s Dearborn, falsified case definition (you will see later, in an announcement by the Mayo Clinic, below).

US Patent # 6,045,804
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,045,804.PN.&OS=PN/6,045,804&RS=PN/6,045,804

This patent reveals they know LYMErix causes a systemic disease like chronic Lyme,  and in this patent they reveal their intended monopoly on post-LYMErix testing for the USA and Canada as they claimed in their advertising:
"Additional uncertainty may arise if the vaccines are not completely protective; vaccinated patients with multisystem complaints characteristic of later presentations of Lyme disease may be difficult to distinguish from patients with vaccine failure."

"The present invention provides a method useful to detect a B. burgdorferi infection in a subject. The method provided by the invention is particularly useful to discriminate B. burgdorferi infection from OspA vaccination, although it is sufficiently sensitive and specific to use in any general Lyme disease screening or diagnostic application. Thus, the method of the invention is particularly appropriate for large scale screening or diagnostic applications where only part of the subject population has been vaccinated or where the vaccination status of the population is unknown. "

 

Persing and Sigal later reveal that the Western Blots in both vaccine trials were unreadable.  Both vaccine trials used MarDx test strips and said they were using the Dearborn method to assess the efficacies of these vaccines.  Arthur Weinstein was the Data Safety Monitor for one of those trials and was also a participant in the Dearborn scam.  Obviously Weinstein never looked at any of the data he was safety-monitoring since the Western Blots were unreadable.  In reality, neither OspA vaccine trial group could tell whether or not OspA prevented Lyme, so those vaccine trial reports were research fraud events and reports.
This Persing-Schoen RICO-RICO Patent 6,045,804, is also written up this PubMed report, co-written by Yale’s Robert Schoen:
Borrelia burgdorferi enzyme-linked immunosorbent assay for discrimination of OspA vaccination from spirochete infection.
http://www.ncbi.nlm.nih.gov/pubmed/8968914


 

Dattwyler, Raymond J. - owns a patent that describes OspA as Pam3Cys.  Therefore it  could not have been a blood-stream-injected “vaccine,” because it is a human TLR2/1 agonist.  This Dattwyler patent is for an inhalation form of OspA/Pam3Cys.  Lung immunity is different from injecting fungal antigens directly into the blood stream:

 (US20090324638) LIVE BACTERIAL VACCINE 

"A lipidation/processing reaction has been described for the intact OspA gene of B. burgdorferi. The primary translation product of the full-length B. burgdorferi OspA gene contains a hydrophobic N-terminal sequence, of 16 amino acids, which is a substrate for the attachment of a diacyl glyceryl to the sulflhydryl side chain of the adjacent cysteine (Cys) residue (at position 17). Following this attachment, cleavage by signal peptidase II and the attachment of a third fatty acid to the N-terminus occurs. The completed lipid moiety, a tripalmitoyl-S-glycerylcysteine modification, is termed Pam3Cys (or is sometimes referred to herein as Pam(3)Cys or Pam3Cys). It has been suggested that the lipid modification allows membrane localization of proteins, with polypeptide portions exposed as immune targets. In addition to serving as targets for the immune response, Pam3Cys-modified proteins, such as OspA, have been reported to act as potent inflammatory stimulants though the toll-like 2 receptor mechanism (TLR2).
http://patentscope.wipo.int/search/en/detail.jsf?docId=US42934470&recNum=9&maxRec=30&office&prevFilter&sortOption=Pub+Date+Desc&queryString=tripalmitoyl+cysteine+or+Pam3Cys+and+Epstein-Barr&tab=NationalBiblio

 

 

========== 

The Mayo Clinic advertised the RICO within the RICO – a patent they were the assignee and would have gotten royalties (6,045,804); CT AG and now Senator Richard Blumenthal’s staff were interested to know if this RICO cabal including Yale, Imugen and Corixa ever advertised their intended monopoly on post-LYMErix blood testing for North America “where the vaccination status was unknown.”  This is one example.  Yale also advertised this new test:

Can be found at:
https://groups.google.com/forum/#!original/sci.med.diseases.lyme/D6v-QHQdMbc/WupHjKwFilIJ


”http://www.mayo.edu/comm/mcr/news/news_361.html

“Mayo Clinic Rochester News

“      Tuesday, August 4, 1998

“New Tests Set Standard for Diagnosing Lyme Disease

ROCHESTER, MINN. — Mayo Medical Laboratories and IMUGEN Inc. announced today the newest and most accurate test series  available for diagnosing Lyme disease. The tests also are  the only reliable means of diagnosing Lyme disease in people who have been vaccinated against Lyme disease.

“Mayo Medical Laboratories, the laboratory for Mayo Clinic, and IMUGEN Inc. of Norwood, Mass., are jointly offering the new proprietary tests through local hospitals and clinics. Availability of the new tests coincides with the anticipated release of new Lyme disease vaccines, such as the widely-publicized LYMErix and ImuLyme.
”In research trials, all other Lyme tests have been shown to produce false-positive results in people vaccinated against Lyme disease. Moreover, the downstream costs of medical care delivered on the basis of just one false-positive Lyme test can be as much as $15,000.

“According to Dr. David Persing, a Mayo Clinic molecular biologist involved in the discovery of the new test components, physicians now have a new and more reliable means of diagnosing patients who present with symptoms of Lyme disease.

"These tests should help reduce the human and financial costs associated with the number of undiagnosed, misdiagnosed, untreated or improperly treated patients," Dr. Persing added.
”Scientists at IMUGEN, recognized nationally as the leading reference laboratory for tick-borne diseases, are responsible for developing the highly accurate immunologic methods to utilize Dr.Persing’s discovery.

"Diagnosing Lyme disease has been highly problematic for a long time," said Victor Berardi, chief executive officer of IMUGEN, whose laboratories have performed more than a half-million Lyme disease tests. "Our new tests will greatly help physicians in distinguishing patients who are actually infected from those who aren’. Furthermore, the accuracy of these tests will not be affected by Lyme vaccine. In any case, the tests will help physicians render more appropriate and cost effective care."

“Lyme disease is a tick-borne illness that if left undiagnosed or untreated can severely damage the human heart and nervous system. Nationally more than 16,000 cases of Lyme disease were reported to the Centers for Disease Control and Prevention (CDC) in 1996. The majority of cases were reported in New England and the Northeast. The CDC reports that the overall number of Lyme disease cases could climb to 25,710 by the year 2000.

“In a study of 10,936 people in states with a high incidence of Lyme disease, one new vaccine proved 79 percent effective at preventing Lyme disease infections after complete dosage. Given the potential popularity of the vaccine, and the recent epidemic of Lyme disease in the Northeast, the new tests offered by Mayo Medical Laboratories and IMUGEN will be of considerable value.
”The new Lyme disease tests detect multiple classes of antibody isotypes, enabling them to discriminate between the vaccine and a true Lyme infection. Existing Lyme disease tests, however, have shown to produce false-positive results in patients vaccinated for Lyme disease.

“IMUGEN Inc. of Norwood, Mass., is a pioneer in the research, development and testing of tick-borne diseases, including Lyme disease, babesiosis and ehrlichiosis. For the past decade, IMUGEN has provided clinics and hospitals in the Northeast with

high-quality serologic testing from its facilities in Norwood, Mass., and Southhampton Hospital in Southhampton, N.Y. For more information, call 781-255-0770.

“Mayo Medical Laboratories is the laboratory for Mayo Clinic and provides lab services to community-based healthcare organizations throughout the nation and world. Mayo Medical

Laboratories draws from the expertise of Mayo Clinic’s 1,600 physicians and scientists who provide specialized consultation on test selection, utilization and interpretation.

“For information, call 800-533-1710.
       ###

“Contact:

“Tom Huyck

“507-284-0003 (days)

“507-284-2511 (evenings)”

-------------------------

 

 

CDC/ALDF’s Valid Biomarkers in “Lyme Disease,” not used in Klempner/IDSA’s Lyme disease “re-treatment” study, and “guidelines. ” 

Here we reveal the valid biomarkers of illness in “Lyme Disease” discovered by the CDC’s ALDF.com (and later IDSociety.org) cabal, yet they were not used for the assessments or outcomes of Mark Klempner’s Lyme disease “re-treatment” study or IDSociety.org’s “Guidelines on the Diagnosis and Treatment of Lyme disease.” 

Through this contrast we demonstrate criminal acts of those responsible for the Lyme disease scam.  The scam was essentially the CDC
falsifying the testing and “case definition” at a conference in Dearborn, MI (1994) in order to falsely qualify their OspA and other patent  outcomes.  The purpose of the Dearborn stunt was to falsely claim that “Lyme disease is only an HLA-linked hypersensitivity or allergy response,” knowing otherwise.  Criminal charges will include “fraud with malice” because of the slander and libel against their victims.  If “fraud on the government” is performed by government employees “with malice” or intent to cause harm, they do not have immunity from criminal charges.  Those chargeable in the criminal Lyme disease scam include CDC officers Allen Steere, Alan Barbour, Barbara Johnson and Mark Klempner; NIH employee Edward McSweegan; NYMC and Yale’s Durland Fish; and their associates with the ALDF.com. 


These perpetrators claimed that vector borne diseases were a "rich vein of gold from which to mine…” patent royalties (Alan Barbour).  There are more quotes revealing clear malicious intent towards their victims in the 2003 complaint to the UN about these crimes here, in a formal complaint to the UN (which they answered by saying they needed volumes of complaints):  http://www.actionlyme.org/UN_PETITION.htm 

This science of fungal antigen-induced immunosuppression exposes 1) the mechanisms that produce the Autism pandemic, 2) the nature of Bioweapons (stealth, no antibodies), and that 3) the CDC and the NIH are embarrassed that they allowed this bunch of clowns to run a “OspA/Pam3Cys is a vaccine” scam.  But spirochetes are not typical bacteria.  They are their own phylum and shed fungal antigens.  They might as well be called myco-chetes. 


1. Mechanisms that produce the autism pandemic parallel chronic Lyme disease

 

The link between Lyme disease (the real name is Relapsing Fever) and Autism is the fungal antigen OspA (Pam3Cys). OspA and antigens like it are shed all the time in borreliosis or Relapsing Fever (RF) in a process called blebbing. This blebbing or shedding of fungal, lipopeptide surface antigens has something to do with RF’s immune evasion.  But they cause immunosuppression, the reactivation of latent herpesviruses, and also tolerance-spreading from TLR2/1-agonist tolerance to viral (Harding, http://www.ncbi.nlm.nih.gov/pubmed/20660347) and to other bacterial type tolerance, such as LPS/TLR4-agonists (Redmond, http://www.ncbi.nlm.nih.gov/pubmed/16461741). 

 

Thimerosal is put in vaccines to prevent fungi. It has been known at least since the 1950s that you can’t inject fungi together with viruses into a mammal as this causes the viruses to become activated and lethal (Mice infected with mycoplasma plus a hepatitis virus: http://www.ncbi.nlm.nih.gov/pubmed/13109101).

 

Conversely, pediatricians give children with cold viruses antibiotics to prevent secondary ear infections because they knew one infection tends to invite another. The CDC’s influenza mortality data does not directly mention that the vast majority of deaths were due to the secondary pneumonia infections. In the 1918  Spanish Flu pandemic, it was again the secondary, mycobacterial infections that killed most people.  In these examples, you’ve see the very real dynamic of fungal-viral synergy working in both directions: fungal infections assist viral, and viral invections invite bacterial. 

 

2. The nature of bioweapons – stealth or no HLA- or hypersensitivity-response

 

The second reason the CDC does not want anyone to know about the mechanisms of illness from spirochetes constantly shedding/blebbing outer surface fungal lipoproteins and with antigenic variation ("multi-clonal populations overwhelm the immune system," Barbour’s US Patent 6,719,983 and related), "even if infected with just one spirochete" (http://www.ncbi.nlm.nih.gov/pubmed/14861181, Barbour, et al, referenced that “single spirochete” report), is that the description of a bioweapon happens to match Alan Barbour’s "multiclonal populations... overwhelm the immune system." A bioweapon will have no antibodies that identify the original detonator infection.

However, others are leaking this information. And Russia knows the NYMC-associated Russians were HLA-datapharming (meaning they were looking at local populations’ HLAs) all over the world. Bioweapons are not designed against a population who will make strong, robust, healthy antibodies. Stealth bioweapons target  populations where there is no association to HLA groups that will produce many antibodies and potentially identify the original infections. See “Ethnic Bioweapons” in Wikipedia where the Russian Duma banned the export of their  populations’ DNA to America in 2007 for this reason.

 

3. NIH and CDC are embarrassed that they allowed these scientifically incompetent people to run "Lyme Disease.”

The fungal OspA non-vaccines caused the same systemic, “multi-system” (Persing and Schoen), “protean” (Luft) disease as “Chronic Lyme,” and the NIH and CDC are terrified of everyone knowing how badly that has screwed up all U.S. medical science for decades. The crooked USA “government” currently stands behind the IDSA’s spin on short-term-treatment-only because they know Late Neurologic Chronic Lyme is really about reactivated latent herpesviruses and systemic fungal and bacterial diseases. It’s AIDS-like.


If the USDA.gov and CDC wanted to hide an accidental release of the modified-for-the-hard-bodied-Ixodes-tick African Bird Borreliosis anserina (called burgdorferi now), they certainly picked the wrong bumbling, obtuse, low-life gang to try to pull it off.  Deploying vicious, foul-mouthed, stalking, slandering, libeling cowards who used criminal “anonymous internet harassment” and all their other transparent and stupid lab stunts such as what Steere did to falsify the Dearborn case definition and this moronic “Klempner study,” was the wrong way to play it. Western society is just not familiar with such vicious, aggressive sledgehammer “treatment” of very sick people from a self-alleged “medical society.” Their aggressive behavior towards very sick people is classic “defensive behavior” (means aggressive behavior, believe it or not, but that’s psychiatry) and betrays their guilt.

 

Post Sepsis Syndrome

Despite all this, the new news is that the NIH has endorsed the description of all the similar chronic fatiguing illnesses – CFIDS, ME, Fibromyalgia, Lyme and possibly Gulf War Illness - by Washington University St Louis (wustl.edu) in summer of 2014, shown below. We’ll just agree with them and call these diseases post-sepsis syndrome (PSS). PSS implies ongoing, active infections, and not just the post-septic shock’s well-known organ, tissue and immune system damage. They, wustl and the NIH, refer to the herpesviruses, especially Epstein-Barr in PSS.

 

Notice that that PSS description is in parallel with what happens when a child is immunosuppressed naturally or is immunosuppressed because she/he has a concurrent active bacterial infection, and is vaccinated anyway. Or, in the cases where the vaccine vial has been contaminated with mycoplasma [which is “myco” (which is fungal)], which is like OspA, and causes immunosuppression and the lack of antibody production. The child will get the viruses instead of the protection, as reported by the CDC themselves. Congenital Rubella causes Autism and that was the reason they decided to vaccinate against it in the first place. Measles is also a neurotropic virus. We call the general dynamic Fungal-Viral Synergy.


 

The “IDSA Guidelines” are intended to give the appearance that the Lyme cabal believes the Dearborn case definition is real.  But most of the cabal members were present for the Dearborn stunt. For example, Gary Wormser’s contribution was that the Steere’s research-fraud criteria was only 15% accurate in IgG (detects 9/59 cases), or misses 85%.


In 1997 Mark Klempner received a $4.7 million grant to perform research fraud and then declare that more treatment does not help Lyme victims. The IDSociety.org’s “Guidelines” on the diagnosis and treatment of Lyme disease are based on this bogus Klempner report.

Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease
http://content.nejm.org/cgi/reprint/345/2/85.pdf 

There were numerous fraudulent events in that Klempner study design and in the results-reporting. 

 

  • Klempner used the falsified Dearborn case definition as the inclusion/exclusion criteria. Dearborn was not FDA-valid, was invented via research fraud by Allen Steere in Europe in 1992, and was not even a consensus at that 1994 Dearborn consensus conference.
  • Two-thirds of Klempner’s “re-treatment” victims never had IV ceftriaxone before, yet he claimed he was retreating with the standard of care at the time, which was 30 days of ceftriaxone. Two-thirds of those patents were not "re-treated," so there is no data here to report. 
  • Klempner also did not report which DNA primers he used to detect “NO LYME” in the spinal fluid of his victims (see the DNA & RNA Primers Shell Game). It turns out Klempner used the OspA gene, which undergoes antigenic variation and is not likely to be found with OspA primers from spirochetes fresh out of a tick. And in fact, whenever Mark Klempner did find such OspA-gene-positive-DNA in the spinal fluid of his potential victims, he rejected them from the study. Not only did Klempner say in his write up of the report protocol that if they were positive for Bb DNA in the spinal fluid, they would be rejected from the study—this actually happened. We know of at least one person who had Bb DNA in her spinal fluid that Klempner rejected from the study, yet Klempner did not report this. He said publicly at the 2001 Rhode Island Diseases of Summer Conference at South County Hospital that there were not any cases of DNA-positive Lyme to be found among his study candidates. (We have him on audiotape.)

 

In 2005 Klempner wrote 2 important reports; one with a man named Kaplan at UConn and another with Gary Wormser. In the report with Wormser, they revealed that there were 2 kinds of Lyme: The Dearborn, HLA-linked arthritis in a knee kind, and the other, the 85%, the neurological, seronegative kind. Once again we heard Lyme arthritis cases—cases where the patients are not actually sick—are the only ones allowed to have a disease. That is, the only people who test positive to the false Dearborn case definition have a genetic, HLA-linked arthritis or hypersensitivity; the “C6 Peptide Test” is the same—it only detects Lyme arthritis:
A case-control study to examine HLA haplotype associations in patients with posttreatment chronic Lyme disease.
“Patients generally feel well aside from their arthritis symptoms.”
http://www.ncbi.nlm.nih.gov/pubmed/16107953


In the report with Kaplan, Klempner reported that these people had no neurological compromise and therefore their symptoms were psychiatric:

"Cognitive function in post-treatment Lyme disease: do additional antibiotics help?"
"CONCLUSION:
"Patients with post-treatment chronic Lyme disease who have symptoms but show no evidence of persisting Borrelia infection do not show objective evidence of cognitive impairment. Additional antibiotic therapy was not more beneficial than administering placebo." http://www.ncbi.nlm.nih.gov/pubmed/12821733

Everyone knows that's false. Mark Klempner himself reported extensively about cognitive impairment and biomarkers of central nervous system degradation. Klempner, in addition to finding that Lyme was not curable with IV ceftriaxone—that is, it does not kill all the spirochetes, even without cells to hide within—he found that the majority (79%) of Lyme victims have a unique sign or biomarker of a nerve and brain degrading enzyme called matrix-metalloproteinase-130.

Here are those 2 reports:

Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosis.
"Neurologic manifestations of Lyme disease include meningitis, encephalopathy, and cranial and peripheral neuropathy….The 130-kDa MMP was found without the 92-kDa MMP9 in the CSF of 11 (79%) of 14 patients with neuroborreliosis and only 7 (6%) of 118 control patients (P < .001). This pattern of CSF gelatinase activity may be a useful marker for neuroborreliosis. http://www.ncbi.nlm.nih.gov/pubmed/9466528
FULL TEXT: http://www.actionlyme.org/Retro_Klempnerization.htm

  and

Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro.
"The Lyme disease spirochete, Borrelia burgdorferi, can be recovered long after initial infection, even from antibiotic-treated patients, indicating that it resists eradication by host defense mechanisms and antibiotics…. The ability of the organism to survive in the presence of fibroblasts was not related to its infectivity. Fibroblasts protected B. burgdorferi for at least 14 days of exposure to ceftriaxone. Mouse keratinocytes, HEp-2 cells, and Vero cells but not Caco-2 cells showed the same protective effect. Thus, several eukaryotic cell types provide the Lyme disease spirochete with a protective environment contributing to its long-term survival."
 http://www.ncbi.nlm.nih.gov/pubmed/1634816
FULL TEXT: http://actionlyme.org/Mark_Klempner_Fibroblasts.htm 


Mark Klempner also wrote in 1998 that OspA was the cause of anti-myelin antibodies or probably contributed to the MS form of Lyme. (He may have meant OspC, since that was my reading of Roland Martin's 1988 "Lyme causes Multiple Sclerosis" report, but regardless, MS is not a personality or anxiety disorder):
Is it thee or me?--autoimmunity in Lyme disease.
http://www.ncbi.nlm.nih.gov/pubmed/10581067 
http://actionlyme.org/KFORSCHNER_DISCOVERS_LYME_TOXIN.htm


According to Mark Klempner, Lyme is incurable, causes nerve and brain degrading enzymes as a marker of this terrible disease, and antibodies against OspA cause anti-myelin antibodies or causes MS. But later he performed the research fraud reports where Lyme is nothing but psychiatrically induced imaginings of disability and cognitive dysfunction.

 



 

The other biomarkers discovered by the same persons who libel us with the likes of Munchausen’s and Munchausen’s-by-Proxy accusations?
 

A) MMP-130 - Klempner as shown above.

 

B) ROBERT SCHOEN and GFAp, or glial-fibrillary acidic protein. GFAp is found in the CNS as a biomarker of glial cell degradation in late chronic neurologic Lyme victims:

The Lyme Disease Vaccine: Conception, Development, and Implementation
"Other peripheral neuropathies and Lyme meningitis are also seen at this stage. In late-stage disease, the central nervous system may be involved. A new diagnostic test measuring glial fibrillary acidic protein in cerebrospinal fluid may prove to be a useful tool for measuring such involvement (20)." 
http://annals.org/article.aspx?articleid=713400

 

C) SIGAL and BARBOUR and Anti-heat-shock antibodies (anti-flagellar antibodies)

H9724, a monoclonal antibody to Borrelia burgdorferi's flagellin, binds to heat shock protein 60 (HSP60) within live neuroblastoma cells: a potential role for HSP60 in peptide hormone signaling and in an autoimmune pathogenesis of the neuropathy of Lyme disease.
"Although Borrelia burgdorferi, the causative agent of Lyme disease, is found at the site of many disease manifestations, local infection may not explain all its features. B. burgdorferi's flagellin cross-reacts with a component of human peripheral nerve axon, previously identified as heat shock protein 60 (HSP60). The cross-reacting epitopes are bound by a monoclonal antibody to B. burgdorferi's flagellin, H9724. Addition of H9724 to neuroblastoma cell cultures blocks in vitro spontaneous and peptide growth-factor-stimulated neuritogenesis. Withdrawal of H9724 allows return to normal growth and differentiation. Using electron microscopy, immunoprecipitation and immunoblotting, and FACS analysis we sought to identify the site of binding of H9724, with the starting hypotheses that the binding was intracellular and not identical to the binding site of II-13, a monoclonal anti-HSP60 antibody. The current studies show that H9724 binds to an intracellular target in cultured cells with negligible, if any, surface binding. We previously showed that sera from patients with neurological manifestations of Lyme disease bound to human axons in a pattern identical to H9724's binding; these same sera also bind to an intracellular neuroblastoma cell target. II-13 binds to a different HSP60 epitope than H9724: II-13 does not modify cellular function in vitro. As predicted, II-13 bound to mitochondria, in a pattern of cellular binding very different from H9724, which bound in a scattered cytoplasmic, nonorganelle-related pattern. H9724's effect is the first evidence that HSP60 may play a role in peptide-hormone-receptor function and demonstrates the modulatory potential of a monoclonal antibody on living cells."
http://www.ncbi.nlm.nih.gov/pubmed/11860186

 

So they're saying antibodies against flagellin causes some pathology, while at the same time saying band 41 means nothing and you have a non-disease. It happens to be for the very reason - says Barbour - that antibodies against flagellin cause cross-reactive antibodies against human heat shock protein-60 that there is no flagellin vaccine. So, because the anti-flagellar antibody causes harm and damage, the crooks say if you HAVE that antibody, it means you're psychiatric and don't have a real disease.

 

D) LENNY SIGAL and QEEG or electroencephalograms (Sigal = Munchausen's accuser)

QEEG and evoked potentials in central nervous system Lyme disease.
"Quantitative EEG, flash visual evoked potentials, auditory evoked potentials to common and rare tones, and median nerve somatosensory evoked potentials were obtained from 12 patients with active CNS Lyme disease and from 11 patients previously treated for active CNS Lyme disease. Abnormal QEEG and/or EPs were found in 75% of the active Lyme disease patients and in 54% of the post CNS Lyme disease patients. Three different types of neurophysiological abnormality were observed in these patients includingQEEG slowing, possible signs of cortical hyperexcitability, and focal patterns indicating disturbed interhemispheric relationships. In patients tested before and after treatment QEEG and EP normalization was associated with clinical improvement."
http://www.ncbi.nlm.nih.gov/pubmed/7554300 
http://www.actionlyme.org/MUNCHAUSENS.htm
in http://www.amazon.com/Lyme-Disease-Key-Diseases-Series/dp/0943126584 
 

E) ALLEN STEERE and Brain SPECT or Hypoperfusion

Reversible cerebral hypoperfusion in Lyme encephalopathy.
"Lyme encephalopathy (LE) presents with subtle neuropsychiatric symptoms months to years after onset of infection with Borrelia burgdorferi. Brain magnetic resonance images are usually normal. We asked whether quantitative single photon emission computed tomography (SPECT) is a useful method to diagnose LE, to measure the response to antibiotic therapy, and to determine its neuroanatomic basis. In 13 patients with objective evidence of LE, SPECT demonstrated reduced cerebral perfusion (mean perfusion defect index [PDI] = 255), particularly in frontal subcortical and cortical regions. Six months after treatment with 1 month of intravenous ceftriaxone, perfusion significantly improved in all 13 patients (mean PDI = 188). In nine patients with neuropsychiatric symptoms following Lyme disease, but without objective abnormalities (e.g., possible LE), perfusion was similar to that of the treated LE group (mean PDI = 198); six possible LE patients (67%) had already received ceftriaxone prior to our evaluation. Perfusion was significantly lower in patients with LE and possible LE than in 26 normal subjects (mean PDI = 136), but 4 normal subjects (15%) had low perfusion in the LE range. We conclude that LE patients have hypoperfusion of frontal subcortical and cortical structures that is partially reversed after ceftriaxone therapy. However, SPECT cannot be used alone to diagnose LE or determine the presence of active CNS infection."
http://www.ncbi.nlm.nih.gov/pubmed/9409364

  

F) STEERE and YALE on Lyme Causing Lupus: Antiphospholipid antibodies (probably more likely to be due to the reactivated EBV, but we will look more closely later)

Reactivity of neuroborreliosis patients (Lyme disease) to cardiolipin and gangliosides.
"A subset of patients (50%) with neuroborreliosis (Lyme disease) showed IgG reactivity to cardiolipin in solid phase ELISA. In addition, a subset of patients with neuroborreliosis (29%) and syphilis (59%) had IgM reactivity to gangliosides with a Gal(beta 1-3) GalNac terminal sequence (GM1, GD1b, and asialo GM1). Anti-ganglioside IgM antibodies were significantly more frequent in these two groups of patients compared to patients with cutaneous and articular Lyme disease, primary antiphospholipid syndrome, systemic lupus erythematosus and normal controls. Correlative evidence and adsorption experiments indicated that antibodies to cardiolipin had separate specificities from those directed against the gangliosides. IgM antibodies to Gal(beta 1-3) GalNac gangliosides appeared to have similar specificities since these were positively correlated and inhibitable by cross adsorption assays. Given the clinical associations of patients with neuroborreliosis and syphilis with IgM reactivity to gangliosides sharing the Gal(beta 1-3) GalNac terminus, we suggest that these antibodies could represent a response to injury in neurological disease or a cross reactive event caused by spirochetes." 
 http://www.ncbi.nlm.nih.gov/pubmed/8410057 
FULL TEXT:  http://www.actionlyme.org/STEERE_AND_LUPUS_LYME.htm

 

G) JJ HALPERIN and Quin or quinolinic acid found in the central nervous system, which is a product of the immune response against a bacterial infection (JJ Halperin)

Neuroactive kynurenines in Lyme borreliosis.
"In patients with encephalopathy, serum QUIN was elevated with corresponding increments in CSF QUIN. Lymphokine concentrations were not consistently elevated. We conclude that CSF QUIN is significantly elevated in B burgdorferi infection--dramatically in patients with CNS inflammation, less in encephalopathy. The presence of this known agonist of NMDA synaptic function--a receptor involved in learning, memory, and synaptic plasticity--may contribute to the neurologic and cognitive deficits seen in many Lyme disease patients...."
http://www.ncbi.nlm.nih.gov/pubmed/1531156 

 

H) HALPERIN, DATTWYLER, “Lyme Is associated with  ALS”:

Immunologic reactivity against Borrelia burgdorferi in patients with motor neuron disease.
"Of 19 unselected patients with the diagnosis of amyotrophic lateral sclerosis (ALS) living in Suffolk County, New York (an area of high Lyme disease prevalence), 9 had serologic evidence of exposure to Borrelia burgdorferi; 4 of 38 matched controls were seropositive. Eight of 9 seropositive patients were male (8 of 12 male patients vs 2 of 24 controls). Rates of seropositivity were lower among patients with ALS from nonendemic areas. All patients had typical ALS; none had typical Lyme disease. Cerebrospinal fluid was examined in 24 ALS patients—3 (all with severe bulbar involvement) appeared to have intrathecal synthesis of anti-B burgdorferi antibody. Following therapy with antibiotics, 3 patients with predominantly lower motor neuron abnormalities appeared to improve, 3 with severe bulbar dysfunction deteriorated rapidly, and all others appeared unaffected. There appears to be a statistically significant association between ALS and immunoreactivity to B burgdorferi, at least among men living in hyperendemic areas."
http://www.ncbi.nlm.nih.gov/pubmed/2334308
FULL TEXT: http://www.actionlyme.org/ALSLYME47.htm 

 

I) STEERE and NITRIC OXIDE in the brain (by Allen Steere):

Borrelia burgdorferi and Escherichia coli lipopolysaccharides induce nitric oxide and interleukin-6 production in cultured rat brain cells.
http://www.ncbi.nlm.nih.gov/pubmed/7513330 

 

J) BENACH and Anti-ganglioside antibodies 
Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides.
"Patients with neuroborreliosis produce antibodies, mostly of the immunoglobulin M (IgM) class, to gangliosides, particularly to those with Gal(beta 1-3)GalNac terminal sequences. Lewis rats were immunized with a nonpathogenic strain of Borrelia burgdorferi and with a chloroform-methanol extract (nonprotein) of this organism (CM) to determine whether antibodies to B. burgdorferi also recognized gangliosides. Rats were also immunized with asialo-GM1 to determine whether the elicited antibodies recognized antigens in B. burgdorferi. Rats immunized with B. burgdorferi produced low levels of IgM antibodies that cross-reacted with asialo-GM1 and GM1. Rats immunized with CM had marked IgM reactivity to asialo-GM1 and GM1. Immunization with asialo-GM1 resulted in antibodies that cross-reacted with B. burgdorferi antigens. Although antibodies to B. burgdorferi were of both the IgM and IgG classes, those to CM and to asialo-GM1 and GM1 were predominantly in the IgM fraction. Reactivity of the IgM antibodies decreased after adsorption with the heterologous and the homologous antigens, indicating bidirectional cross-reactivity between CM, asialo-GM1, and GM1 and that immunization with one produces antibodies to the other. There was no in vivo deposition of Ig in peripheral nerves, nor was there nerve pathology as a result of immunizations, but IgM antibodies to asialo-GM1 and CM recognized homologous antigens in the nodes of Ranvier of peripheral nerves from nonimmunized rats. This immunization model suggests that antibodies to gangliosides in Lyme disease have a microbial origin and are potentially relevant in pathogenesis."
http://iai.asm.org/content/63/10/4130.full.pdf+html?view=long&pmid=7558329 


K) 1989, PAUL DURAY in IDSA's journal with the most important biomarker of all,.....

Clinical pathologic correlations of Lyme disease.
"Immature B cells can also be seen in the spinal fluid. These cells can appear quite atypical- not unlike those of transformed or neoplastic lymphocytes." -- http://www.ncbi.nlm.nih.gov/pubmed/2814170  
Full Text: http://www.actionlyme.org/IDSA_CLINIPATH_DURAY.htm

 

1992, Duray again in 1992, in Steve Schutzer's review of the 1992 Cold Spring Harbor Conference on Lyme:
Lyme Disease: Molecular and Immunologic Approaches  (book)

"On occasion, these atypical-appearing large lymphocytes have been misinterpreted in biopsy by several laboratories as cells of a malignant lymphoma or leukemia. Bb antigens, then, may stimulate growth of immature lymphocytic subsets in some target organs, as well as in the cerebrospinal fluid (Szyfelbein and Ross 1988). Usual bacterial infections do not produce such lymphocytic infiltrates in tissue. ****These immunoblastoid cells in Bb infections at times resemble those found in Epstein-Barr virus infections.**** Does Bb reactivate latent virus infections in tissues? Do some tick inocula harbor simultaneous infectious agents (ixodid ticks can harbor Rickettsiae, Babesia microti, and Ehrlichia bacteria, in addition to Bb), producing multi-agent infections in some hosts? Further studies can clarify these issues by mans of tissue-based molecular probe analysis." -

Paul Duray, NCI, NIH, Ft. Detrick, at the 1992 Cold Spring Harbor ALDF.com conference, published in Steve Schutzer's Lyme Disease: Molecular and Immunologic Approaches (book)

 2006, The NIH (NINDS’s MS-Lyme Group) group that discovered that *** OspA *** was the cause of the MS/New Great Imitator outcome of Lyme reporting in the New York Times in the summer of 2013 (Martin and Marques, 2006); this article says these OspA like antigens constantly shed by Borreliae cause immunosuppression in the humoral immune system, but apparently a chronic inflammatory state in the central nervous system:

Borrelia burgdorferi Induces TLR1 and TLR2 in human microglia and peripheral blood monocytes but differentially regulates HLA-class II expression.
http://www.ncbi.nlm.nih.gov/pubmed/16783164 

And this report means you might not even have anti-flagellar antibodies (flagellin is a TLR5-agonist) after being exposed to shed fungal OspA like antigens (TLR2/1-agonists):

Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes.
http://www.ncbi.nlm.nih.gov/pubmed/16479520


2013, Same NIH MS-Lyme Group as above, Martin and Marques:

When Lyme Disease Lasts and Lasts – Jane Brody, NYTimes
"Complicating the picture is the fact that some people with PTLDS symptoms apparently never had Lyme disease in the first place, Dr. Marques said in an interview. There are other infectious organisms — Epstein-Barr virus, for example — that can produce similar symptoms and may be the real culprits."
http://well.blogs.nytimes.com/2013/07/08/when-lyme-disease-lasts-and-lasts/

 

2014, Wustl.edu discovers that sepsis is like Lyme, in that the survivors of it are likely to have survived via the immunosuppression (TLR2-agonist tolerance/Endotoxin tolerance), but the result is the reactivation of latent viruses:

Dormant viruses re-emerge in patients with lingering sepsis, signaling immune suppression
"Patients with lingering sepsis had markedly higher levels of viruses detectable in the blood, compared with the healthy controls and critically ill patients without sepsis. Among the sepsis patients, for example, the researchers found that 53 percent had Epstein-Barr virus, 24 percent had cytomegalovirus, 14 percent had herpes-simplex virus, and 10 percent had human herpes simplex virus-7.

"These viruses generally don’t lead to significant illness in people who are healthy but can cause problems in patients who are immune-suppressed. "
http://news.wustl.edu/news/Pages/27015.aspx

FULL JOURNAL REPORT, snippet…

Reactivation of Multiple Viruses in Patients with Sepsis
“Sepsis is the host's non-resolving inflammatory response to infection that leads to organ dysfunction [1], [2]. A current controversial hypothesis postulates that if sepsis pursues a protracted course, it progresses from an initial primarily hyper-inflammatory phase to a predominantly immunosuppressive state [3]–[7]. … However, several issues have limited this approach including lack of consensus that immunosuppression is a clinically important phenomenon [5], [6], [13]…  Latent viruses such as cytomegalovirus are normally held in abeyance by cellular and immune surveillance mechanisms which if impaired, for example by immunosuppressive medications, often result in viral reactivation, replication, and virally-mediated tissue injury [15]–[20]. Sepsis impairs innate and adaptive immunity by multiple mechanisms including apoptosis-induced depletion of immune effector cells and induction of T-cell exhaustion thereby possibly predisposing to viral reactivation and dissemination [21]–[23]. …”   http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0098819

 

2014, Here the NIH agrees that post-sepsis, like wustl above describes, matches their own observations of what happens as a result of Chronic Lyme (EBV reactivated; ie, that being generally accepted as the main driver of MS and Lupus):

NEW, by the NIH: 
Surviving Sepsis: Detection and Treatment Advances

By Carolyn Beans for the National Institutes of Health | August 18, 2014 08:43am ET
http://www.livescience.com/47387-sepsis-diagnosis-treatment-research-nigms.html 

Preventing Secondary Infections
"Some people who survive sepsis can develop secondary infections days or even months later. A research team that included Richard Hotchkiss, Jonathan Green and Gregory Storch of Washington University School of Medicine in St. Louis suspected that this is because sepsis might cause lasting damage to the immune system. To test this hypothesis, the scientists compared viral activation in people with sepsis, other critically ill people and healthy individuals. The researchers looked for viruses like Epstein-Barr and herpes simplex that are often dormant in healthy people but can reactivate in those with suppressed immune systems. [Sepsis Has Long-Term Impact for Older Adults, Study Finds]"



In the end, one wonders how the CDC and IDSA get off saying Lyme has no illness signs or is a somatoform disorder. As long as people don’t know what OspA is, they’ll get away with this charade.



On USA’s Bioweapons from the Congressional Record, 103rd Congress:

 

 

"Methods of using antipersonnel agents undoubtedly vary so that no uniform pattern of employment or operation is evident [make sure it does not produce antibodies, is the short version- KMD]. It is likely that agents will be used in combinations so that disease symptoms will confuse diagnosis and interfere with proper treatment. It is also probable that biological agents would be used in heavy concentrations to insure [SIC] a high percentage of infection [or just use the OspA vaccine- KMD] in the target area.  The use of such concentrations [or the multiple infections it causes, due to the immunosuppression like HIV, Lyme, or LYMErix as acquried immune deficiencies - KMD] could result in the breakdown of individual immunity because the large number of micro-organisms entering the body could overwhelm the natural body defenses [or just infect or inject people with an immune suppressor like OspA from a tick or a syringe, and the reverse will happen: people will acquire multiple infections because their immunity is trashed by OspA- KMD].

 

It is extremely important that people actually read that.  It matches the “single spirochete producing multiple variants” and “these multiple variants each undergoing limitless antigenic variation…,” “could overwhelm the immune system,” claims, especially if they are of the OspA or fungal type.

 

 

Basically these crazy people associated with the CDC and ALDF.com wanted to inject people with the very thing that causes the New Great Imitator outcomes.  It was like a Tuskegee “Bad Blood” experiment on steroids.

 

 

150219,KMD,SASH

 

 

LYMErix #FAILED Anniversary Edition - Ordered off the market by the FDA.

Feb. 26, 2002, the FDA ordered LYMErix off the market because it was causing systemic, "protean (please look that word up)," "multi-system disease," just like Chronic Lyme (and ME/CFS, which are identical). We had started a campaign to get these events reported to the FDA per the recommendation - if you can believe it - of Dennis Parenti at SmithKline in PA in Sep, 1999. About a month earlier Karen Forschner of the Lyme Disease Foundation (Hartford, CT) had gotten me a copy of the Dearborn booklet. (I actually ordered it on the phone from her office in Hartford in June, 1999. I had gone up there to Hartford to complain about the adverse events and said to Karen that we needed to know how the hell we got this standard, since just about no one with Lyme tested positive to Dearborn and also OspA and B were left out, yet they were the "vaccine?" ....)

So, we knew LYMErix was causing "systemic, protean, multisystem disease" just like Chronic Lyme from the patients - who we told how to report to the FDA through the VAERS. It took another 4-5 years to find out exactly what that molecule was, OspA (Pam3Cys). I found its image in a Korean Chem journal as part of an HIV vaccine (?). Pam3Cys is FUNGAL, explaining the "protean, multi-system disease," which starts out by causing immunosuppression and a lack of apoptosis in infected cells. At the same time, we knew EBV did the same thing - inhibited apoptosis of infected cells - and such "EBV-transformed" or "EBV-immortablized" cells were found in the spinal fluid of Lyme victims (Duray). And Dearborn was bogus - I am an analytical chemist and development and validations of analytical methods happened to be what I did for a living at Pfizer. Bogus testing, bogus vaccine, .. and the disease was the same as the vaccine outcome. Clue.

Everyone will recall that when I blew the whistle at the FDA in Jan 2001, I showed the FDA committee that no one agreed with the crooks at Dearborn at that 1994 meeting, and I also said that LYMErix caused immunosuppression (IL-10 and Dattwyler's NK cell activity suppression).  I said this vaccine appears to be activating some latent infection...

It just took a while to figure out why - I could find no structure for OspA for the longest time...
 

Article in the NJ Star-Ledger about LYMErix going down by Ed Silverman

"The decision was a victory for consumer advocates, who have been lobbying the FDA to force Glaxo to withdraw Lymerix.

“It should have never been approved in the first place,” said Karen Forschner of the Lyme Disease Foundation, a nonprofit that recently obtained clinical-trial data that she said raised questions about the extent to which side effects were recorded properly.

“It was based on bad science. It’s a crummy vaccine that’s probably caused significant injury to people, but information wasn’t shared with the FDA or the public,” she said. “This decision will probably save thousands of people from having similar problems.”

"Barbara Fisher, who sits on the FDA advisory panel that last year heard testimony from people claiming injury from Lymerix, agreed that Glaxo’s decision to discontinue the vaccine was overdue."
 

SmithKline was actually issued an ultimatum by the FDA to either withdraw it themselves or the FDA would order it off the market. So, the truth was not that SmithKline voluntarily withdrew it.  SmithKline was threatened by the FDA to yank it themselves or the FDA would yank it.

 

The same mechanism cross-applies in the cases of children getting brain damage from vaccines.  The CDC's and NIH's own science reveals that the vaccination of children with fungal-contaminated vaccines results in the vaccines being reactivated.  In other cases where the kids are getting the viruses instead of the "protection" are the cases where the children are immune suppressed either naturally or because they have some other ongoing infection.  NEVER vaccinate a kid with a cold, if you know what I am saying.

The same reasons doctors came up with the idea of giving kids with colds antibiotics to prevent ear infections, is the same dynamic we are talking about here.  One infection sort of "invites" the others, if you follow me.

More data here in this comprehensive report that ties in all the CDC's. NIH's and BigPharma's research on these matters of vaccination failures or exposures to molds as mechanisms of Acquired Immune Deficiencies such as Autism, Chronic Fatigue Syndrome, ME, Chronic Lyme, etc.

Same paper here: 

New Science-Policy paper on ME/CFS, using the IDSociety.org's own data and Policy-Papers.
 

So, what is the state of the science?  See Chapter 13 regarding IDSA's Policy Papers on Detection of CNS Infections with Mass-Spec-PCR.  

Such testing obviously won't go into any "test kits," sorry CDC & IDSA DNA Profiteers  Time to go to jail, fellas, over your DNA patenteering for test kits and vaccine royalties.  You effed up all science in America for the last 30 years with your blind greed and you put this country in all sorts of peril.

 

Update --- CDC on fungal meningitis-- http://www.cdc.gov/meningitis/fungal.html

Notice that the CDC's diagnostic criteria ^^^ there matches exactly the new Policy Paper by IDSA on using Mass-Spec-PCR to identify CSF pathogens HERE.


Fauci's patent for the treatment of Fungal Meningitis (Chronic Fatigue, Chronic Lyme and LYMErix Disease):

"BACKGROUND OF THE INVENTION

"....Illustrative of specific disease states in treatment of which the present invention can be applied are HIV infection and other diseases characterized by a decrease of T-cell immunity, for example, mycobacterial infections like tuberculosis and fungal infections such as cryptococcal disease. This method also can be used in the treatment of secondary infections that occur in patients with suppressed immune systems, such as the opportunistic infections that occur in AIDS patients. ..."

It's a patented treatment for the immune suppression outcomes of Lyme disease, which is a condition simultaneously denied by the head of the National Institute of Allergy and Infectious Diseases- who owns this patent.

"It is an indescribable experience knowing that what you are doing will have an impact on the lives… of millions of people." —Anthony Fauci, 1993

Yeah, thanks, Ton'.  It's been fabulous.

 


Ignore Vaccine Scare-mongering and Threats

No one should worry about the CDC or any of the MSM "news" outlets or Zuckerheimer threatening to kick Anti-Vaxxers off Facebook or whatever bullshit response we're getting because the incompetent HHS.gov lost control of all narratives.  They, the NIH, CDC, etc., totally lost control of all narratives because they're dumb and have severe credibility issues (that are really criminal issues and they are going to be charged in a few HUGE ones this year). 

And the American Medical Association totally endorses our position:
http://www.globalresearch.ca/american-medical-association-opposes-mandatory-vaccines-medical-ethics-statement/5430563

So, everyone be cool.  We got this.  All USA institutions FAILED and we are not even interested in what they have to say about anything.... even while we proceed with writing up the criminal charges for the USDOJ.  You will see it is all the same data.  The larger truths about medical science, the CDC, and BigPharma are the same truths that will be exposed - and the CDC held accountable for - in the USDOJ criminal charge sheets, two of which are on this homepage: Patents and Biomarkers.

Just don't be distracted by their bullshit scare tactics.  It's all bullshit hysteria from a bunch of cowards.  And there is no kinda low life lower than a coward.  The whole world instinctively finds cowards despicable. 

 

 

 

Khan Acad of Cryme
5 new "Axes" DSM
DCF witnesses demonic
141215homepage
Cryme Trainer 2012
Jan-Nov 2014 home
150216.htm FBI
150103_HOMEPAGE.htm